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ABSTRACT 
Subjective cognitive decline (SCD) refers to concerns – symptoms - 
regarding one’s cognitive functioning, in the absence of objective 
evidence of impairment. SCD has been described as a possible stage 
preceding mild cognitive impairment (MCI) and dementia. The 
characteristics and clinical relevance in relation to subsequent objective 
cognitive decline is however still unclear.  
 
We developed a patient-based comprehensive questionnaire on 
everyday cognitive difficulties. Patients with SCD were followed over 
time, to analyze the associations between SCD and cognitive outcome. 
Furthermore, we investigated the associations between SCD and stress, 
depressive symptoms and CSF AD profiles, and evaluated newly 
published international criteria for SCD, ‘preclinical AD’ and 
subcategories, involving both clinical features and neurochemical 
biomarkers. All participants in the current thesis were patients or healthy 
volunteers at the Sahlgrenska memory clinic in Mölndal.  
 
 We identified specific SCD symptoms that were more frequently 
reported by subjectively impaired patients seeking help for cognitive 
problems, compared to healthy elderly. The self-report instrument 
SASCI-Q is a useful research tool to investigate cognitive symptoms 
further. SCD patients were characterized by relatively young age, high 
educational attainment, high prevalence of stress conditions and 
depressive symptoms, and a family history of dementia. About 40 % of 
patients with SCD declined cognitively over 4±2.9 years – one fourth of 
them converted to dementia. When CSF biomarkers were added, the 
ability to predict MCI, dementia and AD dementia clearly increased. A 
specific profile of subjective cognitive symptoms could not be 
associated with cognitive decline in a mixed SCD+MCI patient sample. 
However, when groups were analysed separately, reporting more 
symptoms was associated with subsequent decline in the SCD group 
whilst reporting less symptoms was associated with subsequent decline 
in the MCI group.   
 
Cognitive symptoms reported by the patient may signify many different 
conditions, and their associations with subsequent dementia should not 
be overstated when there are no objective signs present.  
  
Keywords: cognition; self-assessment; memory: mild cognitive impairment; 
subjective cognitive decline: dementia: Alzheimer’s disease; preclinical AD; 
stress; depressive symptoms; memory clinic. 
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1 SAMMANFATTNING PÅ SVENSKA 
”Vad heter hon nu, hon i den där filmen…?”  
”Vad var det jag skulle hämta i förrådet…?” 
”Va, har jag redan berättat det?” 
Minnesproblem är något de flesta av oss kan känna igen oss i. Hjärnan verkar 
inte alltid vara med på noterna, och dagligen märker vi dess begränsningar. 
Förutom minnesbesvär kan vi exempelvis uppleva svårigheter att koncentrera 
oss, planera, lösa problem, hitta ord eller följa en karta – alla dessa funktioner 
och många fler kan samlas under begreppet ’kognitiva funktioner’. För en del 
personer blir problemen så oroande att de bestämmer sig för att söka sig till 
sjukvården, ofta av rädsla för demenssjukdom. Alzheimers sjukdom är den 
vanligaste orsaken till demens, och innebär en gradvis försämring av kognitiva 
funktioner, orsakade av skadade eller döda hjärnceller.  
På minnesmottagningar utreds personer som söker hjälp för kognitiva 
svårigheter, där det bedöms finnas en risk för begynnande demenssjukdom, 
t.ex. om personen är äldre och upplever en försämring jämfört med tidigare. 
Undersökningen består oftast av samtal/intervju, skattningsskalor, 
hjärnavbildning med t.ex. magnetkamera, och bedömning av kognitiv funktion 
med neuropsykologiska tester. Ofta görs ett ryggvätskeprov, som möjliggör en 
undersökning av tecken på Alzheimers sjukdom i ryggvätskan, som står i 
direkt kontakt med hjärnan. Ryggvätskeprov och hjärnavbildning är exempel 
på ’biomarkörer’ för demens – objektiva indikationer på en sjukdomsprocess i 
hjärnan. Inga idag tillgängliga metoder kan dock ge ett helt säkert svar på om 
en person är på väg att utveckla demens.  
Oftast är personer som söker hjälp på en minnesmottagning någonstans mellan 
friskt åldrande och demens. En kognitiv nedsättning som kan bekräftas med 
standardiserade kognitiva tester, men som ändå inte är på demensnivå, kallar 
vi ’lindrig kognitiv störning’, på engelska mild cognitive impairment (MCI), 
vilket passar in på de flesta personer som utreds på en minnesmottagning. Men 
hos en relativt stor andel av hjälpsökande personer hittar vi inga nedsatta 
testresultat. ’Subjektiv kognitiv försämring’, på engelska subjective cognitive 
decline (SCD), är en term som används inom bland annat demensforskning för 
att beskriva detta tillstånd – vilket alltså innebär att en person har kognitiva 
problem (symptom) som inte kan bekräftas med tester trots omfattande 
undersökning.  
Huvudsyftet för denna avhandling är att undersöka om subjektiv kognitiv 
försämring är kliniskt relevant som en tidig indikator på demenssjukdom. Vad 
karaktäriserar patienter med SCD, jämfört med patienter med MCI och friska 
 äldre? Vilken typ av symptom har personer med SCD? I hur hög utsträckning 
ökar möjligheten att identifiera demens i tidigt skede när personer med SCD 
också har avvikande biomarkörer? Finns det ett samband mellan specifika 
kognitiva symptom vid första undersökningen och demens flera år senare? 
Deltagarna i de fyra studierna är patienter och friska frivilliga som har 
undersökts på minnesmottagningen i Mölndal, vid Sahlgrenska universitets-
sjukhuset.  
Först utvecklade vi ett frågeformulär (studie I). Vi hittade symptom som tycks 
vara mer frekventa hos de som söker sjukvård för sina kognitiva besvär, än hos 
’normalbefolkningen’. I studie II fann vi att patienter med SCD ofta har haft, 
och har, stressproblematik. Patienter med SCD hade också ofta depressiva 
symptom, högre utbildning än övriga patienter, och var förhållandevis unga. I 
studie III utvärderade vi internationella forskningskriterier för SCD, och fann 
att möjligheten att förutsäga MCI och demens tydligt ökar hos patienter med 
SCD om också biomarkörer från ryggvätska är avvikande. På basen av endast 
SCD var risken att utveckla demens förhållandevis liten, även om den var 
större än vad som skulle förväntas i motsvarande åldersgrupp i befolkningen. 
I studie IV fann vi att mycket få specifika kognitiva symptom kan relateras till 
framtida demenssjukdom. Men hos personer som bara hade SCD var 
kopplingen mellan subjektiva symptom och framtida objektiv försämring 
tydligare än hos personer med MCI, som tenderade att underrapportera 
symptom – troligtvis på grund av försämrad insikt.  
På basen av de fyra studierna och andra internationella forskningsresultat dras 
slutsatsen att subjektiva kognitiva symptom hos äldre personer på en 
minnesmottagning överlag är mer relaterade till depressivitet, ångest och stress 
än till framtida demenssjukdom. Dessa personer kan behöva andra insatser  för 
att bättre förstå och förbättra sina kognitiva funktioner. För en mindre andel av 
personer med SCD, 10%, kunde vid dock se demensutveckling vid en 
uppföljning efter fyra år. Särskilt personer med SCD som också har avvikande 
biomarkörer bör därför följas upp vidare på minnesmottagning, eftersom 
risken för en underliggande demenssjukdom då är tydligt större. Vi drar också 
slutsatsen att möjligheten att förutsäga MCI och demenssjukdom på basen av 
en viss profil av symptom tycks vara liten. Insikten i svårigheter kan vara 
nedsatt redan vid MCI, och SCD bör därför inte vara ett krav för att 
diagnostisera MCI. Trots sina brister har subjektiva kognitiva symptom en 
viktig roll eftersom det endast är genom symptom som patienter söker sig till 
sjukvården, där man sedan tar ställning till vidare utredning. 
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DEFINITIONS IN SHORT 
Alzheimer’s disease A neurodegenerative disease 
characterized by certain 
neuropathological changes and a 
gradual progression of cognitive 
and eventually functional 
impairment. Alzheimer’s disease is 
considered the most common cause 
of dementia. 
Awareness The ability to accurately appraise 
aspects of one’s own situation or 
functioning. In this thesis primarily 
used in relation to cognitive 
functioning. 
Biomarker A characteristic that is objectively 
measured and evaluated as an 
indication of normal biologic 
processes, pathogenic processes, or 
pharmacologic responses to a 
therapeutic intervention. 
Dementia A wide range of progressing 
cognitive and functional symptoms, 
caused by disease or injury in the 
brain. Impairment is severe enough 
to interfere with daily functioning. 
Depressive symptoms Continuous and troubling symptoms 
corresponding to, but milder than, 
criteria for major depressive 
disorder, such as depressed mood, 
decreased interest in activities, 
feelings of worthlessness, changed 
activity level, changed sleep 
patterns, changed weight or 
xii 
 
appetite, reduced energy, 
pessimistic thoughts and reduced 
self-esteem. 
Mild cognitive impairment A term aimed at describing an 
intermediate stage between healthy 
cognitive aging and dementia, 
characterized by a limited, but test 
detectable, cognitive decline 
compared to previously, not severe 
enough to interfere with basic 
activities of daily life. 
Objective cognitive impairment Cognitive impairment that may be 
verified by clinical assessment or 
standardized neuropsychological 
assessment, e.g. MCI. 
Preclinical AD A stage preceding MCI, including 
the spectrum of pre-symptomatic 
autosomal dominant mutation 
carriers, asymptomatic biomarker-
positive older individuals at risk for 
progression to MCI due to AD and 
AD dementia, as well as biomarker-
positive individuals demonstrating 
only subtle cognitive decline. 
Stress A state of mental or emotional 
strain or tension resulting from 
adverse or demanding 
circumstances. 
Subjective cognitive decline Self-perceived decline in any 
cognitive domain over time. The 
category SCD does not require 
cognitive testing or confirmation of 
cognitive decline by an informant. 
xiii 
 
SCD is not associated with a 
particular disease or disease state 
per se. When reporting on SCD, the 
specific disease condition to which 
it refers in the particular context 
should be added (e.g. SCD in pre-
clinical AD). 
Symptom A subjective evidence of disease or 
physical disturbance observed by the 
patient. 
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2 INTRODUCTION 
2.1 Short description of the research topic 
Subjective cognitive decline (SCD) refers to concerns regarding one’s 
cognitive functioning, in the absence of objective evidence of impairment [1]. 
In the memory clinic setting, it refers to those patients who are worried for 
dementia development and seek consultation for cognitive decline, although 
their scores on cognitive tests turn out to be in the normal range. Gradual 
decline and a continuous erosion of the brain and functions characterize most 
dementia disorders, which leads to the puzzling question of how the first 
symptoms manifest themselves and if they are possible to measure. This thesis 
deals with the role of SCD in relation to the dementia continuum and strives to 
contribute to answering the question of whether having self-reported cognitive 
difficulties is a risk factor for development of dementia.  
SCD is a complex topic. Subjectively experienced cognitive symptoms are of 
heterogeneous origin and may follow different trajectories. SCD may progress 
to objectively measurable levels, possibly leading to dementia. However, SCD 
may also remain stable, or fluctuate. SCD may reflect actual changes in an 
individual’s normal aging process. Furthermore, SCD may signify objective 
cognitive change caused by factors other than a progressing dementia disorder 
- such as other somatic conditions, or mood disorders. They may reflect 
personality traits associated with negative self-appraisal and worry. Some 
persons with SCD seek help while others do not. Some persons are accurate in 
their self-appraisal – others are not.  
This complex heterogeneity makes SCD difficult to interpret, and not easy to 
manage in the clinic. However, patients with SCD are common help-seekers at 
memory clinics, and more knowledge is needed to understand the 
characteristics and relevance of these symptoms.   
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2.2 Dementia                                                                                   
2.2.1 Definitions and underlying diseases 
Dementia is characterized by progressive loss of cognitive functions, until the 
individual has lost all independency and ability in daily life. The cognitive 
dysfunction is caused by neuronal death and deteriorating synaptic function, 
although the driving mechanisms involved may differ depending on etiology. 
Dementia is not a disease in itself – it is a description of symptoms, a 
syndrome, caused by a disease or injury. A disease leading to dementia may 
be called a ‘dementia disorder’. In the revised Diagnostic and Statistical 
Manual of mental disorders (DSM-V) from 2013 [2], the term dementia has 
been replaced with ‘major neurocognitive disorder’. ‘Mild neurocognitive 
disorder’ signifies earlier stages such as ‘mild cognitive impairment’ (MCI). 
However, ‘dementia’ is still by far the most familiar concept, and will be used 
throughout this thesis. A diagnosis of dementia requires that memory and at 
least one more cognitive domain is significantly impaired compared to 
previous level, which should be determined by neuropsychological 
assessment. Additionally, there should be changes in socioemotional functions 
such as emotional lability, apathy, irritability or changes in social behavior. 
Symptoms should have a duration of at least 6 months [3].  
Alzheimer’s disease (AD) is considered the most common etiology of 
dementia. In persons over 65 years suffering from dementia, approximately 
50-60 % have AD type dementia [4]. AD is characterized by a specific pattern 
of brain pathology including neuritic amyloid plaques and neurofibrillary 
tangles [5]. Except for in more recent research criteria [6, 7], biomarkers 
indicating such pathology are however generally not included in clinical 
criteria for AD dementia or the pre-dementia stages. The diagnosis is 
determined primarily based on the absence of other etiologies, such as vascular 
factors. A typical neuropsychological profile of AD dementia starts with 
decline in episodic memory, followed by language (object naming, verbal 
fluency, semantic categorization) and executive, visuospatial, and attention 
dysfunction [8]. AD dementia may have early onset (before the age of 65) or 
late onset. There are also atypical variations and AD dementia forms 
concurrent with vascular pathology (mixed forms).  
 17 
 
Vascular dementia is the second most common dementia form. The etiological 
overlap between AD dementia and vascular dementia forms is not fully 
determined. Vascular dementia presents in several different forms, such as 
acute onset, multi-infarct, subcortical vascular, mixed or unspecified forms [3]. 
The common denominator is blocked or reduced blood flow to the brain. In 
short, the neuropsychological profile in the subcortical vascular dementia form 
– which is the most frequently occurring vascular form in our sample - is more 
related to dysfunction within attention, speed and executive areas, and less to 
memory functioning, compared to AD [9, 10].  
Less frequent dementia disorders include Lewy-body dementia, 
frontotemporal dementia (subdivided into several different variants) [8] and 
dementia caused by Huntington’s disease, Parkinson’s disease, HIV and 
Creutzfeldt-Jakob [3].  
 
2.2.2 Prevalence and health care costs 
The prevalence of dementia is largely related to aging. The elderly population 
is growing in proportion as well as absolute numbers - globally as well as 
nationally. In 2012, only one country (Japan) had a proportion of individuals 
over 60 years old that exceeded 30% of the population. Projections show that 
many countries e.g. almost all European countries, China and Canada will have 
a similar proportion of older individuals in 2050 [11]. In Sweden, it has been 
estimated that the number of persons over 80 years will increase from 497.000 
to 810.000, from 2010 to 2030. That would mean a 2.5 times greater increase 
compared to the 20-year period between 1990 and 2010 (from 370.000 to 
497.000) [12].  
In 2015, dementia affected over 47 million people worldwide. By 2030, more 
than 75 million people are estimated to be living with dementia, and the 
number is projected to triple by 2050 [11]. In Sweden, the number of 
individuals with dementia was estimated to 160.000 in 2012, with 
approximately 26.000 new cases per year and economic societal costs 
estimated to 63 billion SEK yearly [12, 13]. The national board of health and 
welfare (Socialstyrelsen) concluded in a report from 2014 [14] that methods 
for examining patients with prodromal dementia varies greatly across Sweden, 
and that e.g. level of education and birth country influences the access to 
18 
 
investigation and care. More than half of patients who were diagnosed with 
dementia in primary care received a non-specific diagnosis (‘dementia UNS’), 
which limits the possibilities of appropriate treatment [14]. The number of 
yearly dementia investigations at Swedish memory clinics were estimated to 
14.000 in 2012, of which approximately 50 % resulted in a dementia diagnosis 
[12].  
Several variables affect the prevalence of dementia, such as the age of the 
population and treatment of risk factors, which makes forecasting difficult. The 
forecasted dementia prevalence increases alongside the longer life expectancy 
– from 160.000 Swedish persons with dementia in 2010, to approximately 
230.000 in 2030 [12]. Conditions related to elevated dementia risk - such as 
obesity, diabetes and hypertension – have increased in many countries during 
the last decades. However, the awareness of and treatments for cardiovascular 
risk factors have improved [15]. Additionally, level of educational attainment 
is increasing globally – a factor that has been hypothesized to affect dementia 
prevalence [15]. Thus, the number of individuals with dementia is increasing 
worldwide, however the risk for an individual to develop dementia seems to 
be declining, at least in high-income countries [15].  
 
2.2.3 The early cognitive continuum of dementia 
There is great variability between individuals regarding how cognitive 
functioning changes along with age. Many older adults out-perform younger 
people on cognitive tests, and remain cognitively preserved. However, some 
aspects of memory (e.g. episodic memory) and attention (e.g. dividing or 
shifting attention) often decline with increasing age – while others seem to be 
more preserved (e.g. maintaining concentration; semantic memory). 
Furthermore, decline in executive functions has been described as a key 
contributor of cognitive change in older ages [16]. Sensory changes such as 
visual or auditory impairment may also affect performance on cognitive tasks. 
Consequently, the close and complex inter-relations between aging, cognition 
and dementia complicates the assessment of early signs of dementia.  
Research on early dementia characteristics, especially for AD dementia, focus 
on the cognitive syndrome parallel to the pathophysiological process [17]. The 
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cognitive continuum of dementia refers to the gradual change in cognitive 
processes alongside the neuropathological progression, from the earliest 
symptoms to severe dysfunction. For most dementia conditions, it is still 
unclear how and at which point in time the neuropathological process begins. 
Simply put, functional disability is a consequence of cognitive impairment, 
which is a consequence of neuropathological events – which is a consequence 
of largely unknown factors. With respect to AD dementia, mounting evidence 
suggests that brain pathology is present for more than 20 years before clinical 
diagnosis [18]. A majority of the AD treatment trials have targeted brain 
amyloid accumulation, and have largely failed - believed to be partly a result 
of treatment initiated too late in the disease process when irreversible loss of 
brain cells has already taken place [19] .  
Diagnostic categories designated to describe potential early dementia stages 
have largely been based on observations of test-detectable symptoms – i.e. 
objective cognitive impairment. Although several similar diagnostic categories 
have been used (e.g. cognitive impairment no dementia – CIND [20]; ‘benign 
senescent forgetfulness’ [21]), mild cognitive impairment (MCI) is by far the 
most prominent one. MCI is a term to describe a possible intermediate phase 
between normal cognition and dementia, characterized by cognitive 
impairment that is more pronounced than what would be expected in ‘normal 
aging’. The impairment in MCI is not at the level of affected basic ‘activities 
of daily living’ (e.g. self-caring, self-feeding), but the ability to perform more 
complex daily tasks – ‘instrumental activities of daily living’, such as paying 
bills, cooking or using technical devices, may be somewhat affected. The term 
was first suggested by Reisberg [22], but has since then undergone continuous 
development. One of the first widespread descriptions of MCI [23] entails the 
following criteria: (a) complaint of defective memory, (b) normal activities of 
daily living, (c) normal general cognitive function, (d) abnormal memory 
function for age, and (e) absence of dementia. In 2004, the MCI concept was 
subdivided into: single vs multiple domain MCI (one or more cognitive 
domains affected), and amnestic vs non-amnestic MCI (memory affected or 
not) [24, 25]. In 2011, the NIA-AA (the national institute on aging – 
Alzheimer’s association), suggested that biomarkers should also be included 
in the MCI criteria [6], although purely for research purposes.  
Importantly, even though most studies report that they have applied consensus 
MCI criteria (often referred to as the ‘Petersen criteria’), there are almost as 
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many varying methods used to operationalize these criteria, as there are 
published reports. Nevertheless, numerous studies have presented support for 
increased risk to develop dementia in patients categorized as MCI. In a meta-
analysis covering data from 41 studies, it was concluded that the annual 
conversion rate from MCI to dementia was 5-10% (6.5% to AD; 1.6% to 
vascular dementia - VaD) [26]. The cumulative proportion progressing from 
MCI to dementia averaged 32% across 13 studies using the ‘Petersen criteria’ 
and following over 4.300 individuals with MCI for 3-10 years. However, it 
was also observed that most MCI patients do not convert to dementia within a 
foreseeable time frame [26]. Despite that there is a problem with lack of 
specificity, and that risk estimates vary widely based on different 
methodological factors, the proportion of dementia converters from MCI are 
significantly higher than in the normal population [27], which makes MCI a 
highly relevant clinical concept.  
Although MCI criteria have varied over the years, being categorized as MCI 
always implies a mild - but to some degree objectively detectable - cognitive 
impairment. During the last decade, there has been an increasing interest within 
symptom-based research to investigate even earlier phases of cognitive decline 
– characterized by merely subjective reports of difficulties. This research area 
has grown exponentially in the last 20 years. During the 1980’s and 1990’s, 
subjectively reported cognitive symptoms were only sporadically mentioned 
in scientific papers on dementia, whilst over 300 papers have been published 
with subjective cognitive symptoms as a key topic during the last seven years 
(according to a PubMed search on 20 March 2017). One of the earliest accounts 
was presented by Reisberg in 1986 [28], hypothesizing that - based on clinical 
observations - a phase characterized by only subjective cognitive difficulties 
would last approximately 15 years before the onset of detectable cognitive 
impairment (MCI). The border between subjective and objective cognitive 
functioning, and between subjective cognitive decline associated with disease 
and normal aging are obviously large challenges for this research area.  
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2.3 Signs, symptoms, biomarkers and risk 
factors 
To understand and differentiate between the various methods available for 
assessing pre-dementia phases, it is worth-wile to consider the difference 
between symptoms, signs, biomarkers and risk factors. A ‘symptom’ is “a 
subjective evidence of disease or physical disturbance observed by the patient” 
[29]. A medical ‘sign’ is “an objective evidence of disease especially as 
observed and interpreted by the physician rather than by the patient or lay 
observer” [30]. A ‘biomarker’ has been defined as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” [31]. Thus, ‘biomarker’ can be somewhat regarded as a 
subcategory of medical ‘signs’ (although it may also be used to indicate normal 
biological processes). A ‘risk factor’ is a broader concept including variables 
that increases risk or susceptibility to develop a condition. The overall most 
important risk factor for dementia is old age. For AD dementia, other known 
risk factors are e.g. female sex (onset > 65 years), male sex (onset < 65 years) 
[4] low levels of education, heredity and smoking [32], and for vascular 
dementia forms e.g. prior stroke episodes, elevated systolic blood pressure, and 
excessive alcohol consumption [33].  
It should be noted that the term ‘symptom’ is often used interchangeably with 
‘sign’ in the literature. For example, the preclinical stage of AD is described 
as a ‘pre-symptomatic stage’, even though this refers to an absence of test-
verified signs rather than absence of experienced symptoms. Furthermore, 
symptoms, signs, biomarkers and risk factors should not be mistaken for 
clinical endpoints. The only clinical endpoint of dementia is a manifest 
dementia state fulfilling diagnostic criteria. Neither is any currently available 
symptom, sign, biomarker or risk factor consistent or accurate enough - in 
relation to actual dementia development – to be considered a surrogate 
endpoint (= a substitute for a clinically meaningful endpoint).  
Most methods associated with assessing pre-dementia stages focus on early 
signs. Identification of early signs of dementia may be regarded as resting on 
three pillars: 1) Brain imaging, used to observe structural and functional brain 
changes by techniques such as magnetic resonance imaging (MRI), positron 
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emission tomography (PET), and single-photon emission computed 
tomography (SPECT) ; 2) neurochemical analyses, used to measure protein 
concentrations in the cerebrospinal fluid (CSF) mirroring pathogenic processes 
in the brain; and 3) neuropsychological assessment, used to assess cognitive 
functions and dysfunctions, which may be linked to central nervous system 
disease or injury. These three pillars are all well-established measures of pre-
dementia signs, and may to a varying degree also be described as biomarkers. 
The term biomarker has, within AD research, often been inaccurately limited 
to describe neurochemical markers, although often used also for brain imaging 
markers [34]. Despite its strong and scientifically anchored associations with 
actual and specific brain changes, neuropsychological assessment usually is 
not described as a biomarker, even if it meets most definitions of what a 
biomarker is. The ‘bio’ in biomarker refers to that the object of measurement 
should be biological or intrinsic (from inside the body), but the marker itself 
may be intrinsic or extrinsic [35].  
The differentiation between symptoms, signs, biomarkers and risk factors 
facilitates the understanding of assessment methods as different parts of the 
dementia puzzle, and clarifies the role of SCD. Regarding the 
neuropathological changes of dementia, there are no symptoms – only signs, 
such as structural, functional or neurochemical brain changes. Regarding the 
cognitive changes – there may be both symptoms (self-report, i.e. SCD) and 
signs (measured by neuropsychological assessment, or clinical assessment 
when signs are more manifest). The main hypothesis of the SCD research field 
is that clinically relevant ‘cognitive symptoms’ are measurable before 
‘cognitive signs’. Neuropsychological assessment, brain imaging and 
neurochemical analyses concerns signs. Figure 1 illustrates the chronological 
onset of symptoms and signs in relation to the pathophysiological and clinical 
progression ending with dementia. 
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Figure 1. Symptoms and signs in relation to the pathophysiological and clinical 
progression ending with dementia.  
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2.4 The SCD concept 
 
2.4.1 Prevalence of SCD 
Experiencing subjective cognitive difficulties – in lay-terms often referred to 
as ‘memory problems’ – is common in the general population. The prevalence 
rates of ‘memory complaints’ has been reported as 25-50% in community-
based studies [36], with differing methodology being a likely cause of the large 
variations. Results from a large Norwegian survey reported that nearly half of 
the respondents had minor subjective memory problems, increasing with age 
[37], and the prevalence of experiencing ‘forgetfulness’ was 32% in a British 
health survey. One study compared ‘memory complaints’ in younger vs older 
healthy adults, and found that complaints about memory functioning was 
frequent in both age groups but had different features – e.g. older persons had 
more general complaints and younger person were more often told by others 
that they were forgetful [38]. 
Among persons seeking help at memory clinics (generally consisting of 
individuals who may be categorized as either SCD, MCI or manifest 
dementia), the prevalence of SCD (without MCI or dementia) has been 
reported to be 41% [39]; 18% [40]; 24% [41] and 55% in a younger sample 
[42]. At the Karolinska University hospital memory clinic, the proportion of 
SCD patients increased from 24% during 1999 to 38% in 2005, showing 
increasing rates of SCD help-seeking [43]. 
 
2.4.2 An overview of the SCD research area 
Research on SCD in relation to dementia may be described in terms of four 
overlapping, although different, areas (Figure 2).  
1) Concept development, dealing with how to define and limit the concept of 
SCD. This includes terminology and criteria.  
 25 
 
2) Method development – development and evaluation of different methods to 
measure SCD, and investigation of how different research settings may 
influence findings.  
Areas 1 and 2 serve as a basis for areas 3-4, which deal with the potential 
causes of SCD.  
3) Confounders – the associations between SCD and conditions other than 
dementia, such as other somatic conditions, mood disorders; the influence of 
e.g. demographic factors and personality traits; compromised awareness of 
cognitive functioning; and factors associated with help seeking for cognitive 
symptoms.  
4) Associations with dementia - dealing with the key issue of ‘if and how SCD 
is associated with dementia’, investigated both cross-sectionally and 
longitudinally by analyzing SCD in relation to e.g. neuropsychological tests; 
functional and structural brain-changes; neurochemical markers; genetic 
factors; and actual conversion to detectable cognitive impairment and 
dementia.   
Obviously, SCD may to a varying degree also be present when dementia has 
become manifest – this theme will however not be elaborated on in this thesis 
as it deals only with SCD prior to manifest dementia. 
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Figure 2. A brief overview of the SCD research area.  
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2.5 SCD - concept development 
 
 
 
2.5.1 Terminology 
Several terms have been used interchangeably in this research field: ‘subjective 
cognitive impairment’ (SCI); ‘subjective memory impairment’ (SMI); 
‘subjective memory complaints’ (SMC); ‘subjective cognitive complaints’ 
(SCC), and lately ‘subjective cognitive decline’ (SCD), to mention the most 
frequently used terms. ‘Forgetfulness’ has sometimes been used, and 
‘metamemory’ – the knowledge of one’s own memory capacity – is also a 
related concept [44], however more often used in an experimental than in a 
clinical context. A PubMed search on 20 March 2017 using the terms 
subjective cognitive impairment, complaints or decline, resulted in 239 reports, 
and 248 reports when using subjective memory impairment, complaints or 
decline. Thus, both ‘memory’ and ‘cognition’ are frequently used terms in this 
context. Figure 3 shows the use of different terms over time, based on PubMed 
published reports.  
‘Memory’ may be a preferred term when communicating with patients, 
because ‘cognition’ is a less known concept. However, the term ‘memory’ may 
attain to many different functions, both scientifically and in the common 
language. Health care professionals working in a memory clinic will recognize 
that patients refer to “memory problems” when they talk about very different 
types of dysfunction, such as trouble finding words, difficulties finding one’s 
way, having a hard time focusing on a written text, or difficulties organizing 
an event. For neuropsychologists and other specialized health care 
professionals, these difficulties would translate into difficulties within 
28 
 
different cognitive domains – e.g. language; visuospatial function; 
speed/attention and executive function. Thus, we cannot be sure that we mean 
the same thing when we talk about ‘memory’.  
The terms ‘impairment’, ‘decline’ and ‘complaint’ to designate deficiency 
have also been debated. Stewart [45] suggested the term subjective cognitive 
impairment (SCI) to be used in population contexts and subjective cognitive 
complaints (SCC) to be used in clinical contexts, as a ‘complaint’ more clearly 
refers to an act of help-seeking. It has also been argued that ‘complaints’ should 
not be used at all, because it may come across as a condescending term [46, 
47].  
 
 
Figure 3. Number of PubMed indexed scientific articles using different terms related 
to subjective cognitive symptoms, between 1990 and 2017, according to a PubMed 
search on 20 March 2017. 
0
50
100
150
200
250
300
350
1990-1999 2000-2009 2010-2017
Subjective memory impairment Subjective memory decline
Subjective memory complaints Subjective cognitive impairment
Subjective cognitive decline Subjective cognitive complaints
 29 
 
2.5.2 Toward consensus criteria 
Until recently, ‘subjective cognitive symptoms’ has been a poorly defined 
concept with apparent absence of consensus, which may perhaps be forgiven 
due to its relative novelty. When applied clinically, rather vague classifications 
are sometimes used such as ICD-10 R41.8A (‘mild cognitive impairment, 
subjective’) or Z03.3 (‘observation for suspected nervous system disorder’) 
[3]. In their review of 44 scientific reports in which the theme of subjective 
cognitive symptoms in relation to dementia was addressed, Abdulrab and Heun 
[48] found that no definition included a comprehensive set of criteria and that 
there was no overall agreement between different authors or studies.  
Two sets of criteria were proposed in 2008. Abdulrab and Heun used the term 
‘subjective memory impairment’[48], and Reisberg et al. [47] used the term 
‘primary idiopathic subjective cognitive impairment’. Both criteria require a 
subjective cognitive deficit perceived by the affected individual as a decline 
compared to previous function, with absence of objective cognitive 
impairment and dementia. The criteria proposed by Abdulrab and Heun 
included factors such as frequency of symptoms, age at onset, and duration of 
symptoms. Furthermore, they suggested an additional consideration of gradual 
vs sudden/staggered onset, arguing that gradual onset would indicate 
underlying AD and sudden/staggered onset would indicate VaD. The criteria 
by Reisberg addressed that other conditions, possibly leading to cognitive 
decline, must be ruled out. The two sets of criteria account for the role of 
informant reports in contradictory ways. Abdulrab and Heun suggested that 
informant reports may be used as supportive criteria. In the criteria by 
Reisberg, corroboration by an informant is rather considered a potential 
objective sign of decline, and is thereby incompatible with the limitations of 
the ‘subjective’ patient category. Another distinction between the two sets of 
criteria is the use of single vs multiple domains (Abdulrab and Heun used 
‘memory’; Reisberg used ‘cognition’) [47, 48]. 
In 2012, the Subjective Cognitive Decline Initiative (SCD-I) was launched - 
an international working group with the goal of formulating a research agenda 
for the field [46]. The group consists of main investigators of ongoing 
biomarker initiatives including ADNI (Alzheimer's disease neuroimaging 
initiative), AIBL (Australian imaging, biomarker and lifestyle flagship study 
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of ageing), and DESCRIPA (Development of screening guidelines and criteria 
for predementia Alzheimer’s disease) [46].  
The SCD-I group suggests that the term Subjective cognitive decline ‘SCD’ 
should be used in future research. They argue that ‘decline’ is more appropriate 
than ‘impairment’, since the aim is to identify deterioration from previous 
functioning. Furthermore, they choose ‘cognitive’ over ‘memory’ because the 
first cognitive impairments of AD dementia are not limited to memory, and 
because of the semantic confusion concerning cognition vs memory [46]. The 
SCD-I definition of SCD is “self-perceived decline in any cognitive domain 
over time”. They acknowledge that SCD is not associated with a specific 
disease per se, and that objective cognitive impairment (i.e. MCI) should be 
excluded when SCD is studied in the context of dementia. The SCD-I further 
suggests using an enriched category of SCD – SCDplus, including features to 
increase the likelihood of preclinical AD. Suggested research criteria for ‘pre-
MCI SCD’ [46] are as follows:  
- Self-experienced persistent decline in cognitive capacity in 
comparison with a previously normal status and unrelated to 
an acute event 
- Normal age-, gender-, and education-adjusted performance 
on standardized cognitive tests, which are used to classify 
MCI or prodromal AD 
Criteria included in the enriched SCD plus category:  
- Subjective decline in memory, rather than other domains of 
cognition 
- Onset of SCD within the last 5 years 
- Age at onset of SCD ≥60 years 
- Concerns (worries) associated with SCD 
- Feeling of worse performance than others of the same age 
group 
 
If available or possible to obtain in the respective study: 
- Confirmation of cognitive decline by an informant 
- Presence of the apolipoprotein E (APOE) ε4 genotype 
- Biomarker evidence for AD (defines preclinical AD) 
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MCI and dementia are exclusion criteria, together with presence of psychiatric 
or neurologic diseases (other than AD), or substance abuse, that may explain 
the symptoms. Individual symptoms of depression or anxiety, which do not 
reach the threshold of a disorder, are not considered exclusion criteria [46]. 
With minor exceptions, the SCD-I definition largely corresponds with the 
criteria previously suggested by Abdulrab and Heun [48], and Reisberg [47]. 
Importantly, the SCD-I emphasizes that the characteristics of SCD related to 
preclinical AD are probably variable and expressed heterogeneously.  
Another term has been suggested to describe the stage with the earliest 
objective cognitive signs – ‘subtle cognitive decline’ [7], thus placed between 
SCD and MCI on the cognitive continuum. The criteria for ‘subtle cognitive 
decline’ are not clearly formulated. For example, it has been suggested that the 
term could be used for individuals who perform within normal range on tests 
but demonstrate evidence of decline from their own baseline, or individuals 
with impaired test results only on very challenging tests [7].  The term ‘subtle 
cognitive decline’ has mostly been used in the context of preclinical AD, 
outlined further below.  
The SCD research field would certainly gain from increased stringency 
regarding use of terminology and methodology, and the development of clearer 
criteria is highly warranted. The work on this thesis began before the term SCD 
was established. Nonetheless, ‘SCD’ is used as the key term throughout the 
thesis.  To simplify, the term SCD is also used when referring to previous 
research using other but similar terms such as SMI, SCC or SCI. ‘Subjective 
cognitive symptoms’ is used interchangeably with SCD, and ‘self-reported’ is 
used interchangeably with ‘subjective’.  
 
2.5.3 ‘Preclinical AD’ 
The concept of ‘preclinical AD’ and similar terms may be viewed as the 
pathophysiological counterpart of the symptomatically based SCD concept, 
with respect to AD type dementia. The two concepts are interesting to compare 
because they both deal with the phase prior to objectively measurable cognitive 
decline. However, that is largely the end of the similarities. ‘Preclinical AD’ is 
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used to define several stages of different pathophysiologic changes prior to 
AD, characterized by different outcomes of abnormal biomarkers. SCD may 
“occur in the preclinical stage of AD” [46], but is not a prerequisite for 
preclinical AD criteria - some would describe SCD as a subcategory of 
‘preclinical AD’. However, ‘preclinical AD’ is limited to AD, while SCD is 
not limited to a specific etiology. Thus, the two concepts should not be 
regarded as competing or comparable in validity, but are potentially relevant 
to combine in analyses.  
Jack et al [18, 49] has presented a hypothetical model illustrating the time 
course for five different biological markers of AD, in relation to symptom 
development (Figure 4). An important point of this model is that both 
pathologic and clinical changes occur gradually over time. As this model 
illustrates, pathophysiological changes are likely to occur for a long time 
before clinical signs become evident. A potential problem with the term 
‘preclinical AD’ is that it may be misinterpreted as a stage inevitably leading 
to AD dementia. However, neuropathological abnormality may also occur 
without symptoms ever developing [50, 51]. 
 
 
Figure 4. Revised dynamic biomarkers of the AD pathological cascade model. Reprinted 
from The Lancet Neurology, Vol. 12, Jack et al., Update on hypothetical model of 
Alzheimer’s disease biomarkers, copyright (2013), with permission from Elsevier. 
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In 2012, an international working group convened by the NIA-AA presented a 
conceptual framework for preclinical AD stages, based on current evidence 
[7]. Table 1 outlines a summary of the recommended stages, generally based 
on different combinations of markers of amyloidosis and neurodegeneration. 
Stage 0 (no signs of pathology or cognitive decline) and SNAP (‘suspected 
non-Alzheimer pathophysiology’ = neurodegeneration, but no amyloidosis and 
no cognitive decline) were added to the framework in a later publication [52]. 
One study using the NIA-AA-stages observed an increased risk of progression 
to MCI and AD dementia in the third stage of ‘preclinical AD’ [53]. It was 
concluded that high-level subjective cognitive symptoms may provide a 
sensitive indicator of further cognitive decline in preclinical stages with 
abnormal biomarkers [53]. Another study reported that the greatest severity of 
SCD was observed at ‘preclinical stage 2’, thus when markers for Aβ and tau 
were both abnormal [54].  
 
Table 1. Stages of ’preclinical AD’ and SNAP, recommended by NIA-AA 
 Amyloidosis Neurodegeneration Symptomatology 
Stage 0 - - ‘Asymptomatic’ 
Stage 1 + - ‘Asymptomatic’ 
Stage 2 + + ‘Asymptomatic’ 
Stage 3 + + Subtle cognitive decline 
SNAP - + ‘Asymptomatic’ 
- /+ = negative or positive, as measured by e.g. cerebrospinal fluid (CSF). 
NIA-AA = national institute on aging – Alzheimer’s association; SNAP = 
suspected non-Alzheimer pathophysiology. 
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2.6 SCD - method development 
 
 
 
2.6.1 Assessing SCD 
Even if clearer SCD criteria have been launched, these do not specify which 
methods to use for assessing specific symptoms of SCD – likely because 
numerous different methods, from single questions to comprehensive 
questionnaires, are already applied in different ongoing studies. There is 
currently no ‘gold standard’ measure to assess SCD [55]. In specialized 
settings such as memory clinics, patients may be categorized as having SCD 
because they sought help for cognitive symptoms but cognitive impairment 
could not be verified [55]. That is, no specific instruments or questionnaires 
are in such cases used to categorize an individual as SCD. One review focusing 
on methods used to assess subjective memory impairment identified 44 
relevant studies [48]. In 39 % of the studies, subjective memory impairment 
was determined by asking a single question with a yes/no response, often a 
variation of “do you have trouble with your memory?” The authors criticized 
this method as likely too unspecific and over-inclusive. An additional five 
papers (11 %) used a single question with a graded response. Another 14% 
used sets of questions (scales) with no/yes responses. In 20% of the studies, a 
questionnaire or subscale with scored responses was used [48].  
Several questionnaires exist, varying greatly considering number of items, 
target population, scope, development method, and established properties 
pertaining to validity and reliability. A review of self-report instruments used 
within the 19 studies under the SCD-I umbrella identified 34 self-report 
measures comprising 640 cognitive self-report items [56]. MAC-Q (Memory 
assessment complaint questionnaire) and ECog (Everyday cognition 
questionnaire) were the most commonly used instruments. The ECog is a 39-
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item instrument for informant-report (although used as a self-report measure 
in the ADNI study), with questions related to several cognitive domains [57]. 
The MAC-Q was developed in 1992, with six items selected based on clinical 
experience and on empirical evidence regarding patterns of age-related 
memory loss. It was designed to quantify presence and severity of memory 
complaints in the elderly [58].  These and other questionnaires that stand out 
as frequently used in the literature and/or otherwise of potential interest are 
presented in Table 2.  
Table 2. List of frequently used instruments to measure subjective 
cognitive decline 
Name 
Year 
Country Features 
Participants 
assessed for  
instrument 
development 
Scale 
development 
Example 
studies 
CFQ [59] 
1982 
UK 
25 items 
multi-
domain 
Community-based 
sample 
Expert panel US 
community-
based study 
[60] 
MFQ [61] 
1990 
USA 
25 items 
memory 
domain 
Healthy volunteers Based on 
previous 
instrument 
Australian 
community-
based study 
[62] 
MAC-Q [58] 
1992 
USA 
6 items 
memory 
domain 
Patients with AAMI 
(=MCI) 
Experts Danish 
memory 
clinic study 
[63] 
SMC scale 
[64] 
1996 
The 
Netherlands 
10 items 
multi-
domain 
Community-based 
sample, later 
evaluated for 
differences between 
healthy controls and 
SCD patients. 
Based on 
previous 
instrument 
AMSTEL 
study [64];  
Lisbon 
memory 
clinic study 
[65] 
PROCOG 
[66] 
2006 
USA 
 
55 items 
multi- 
domain 
MCI and mild AD Patients in 
focus groups, 
experts 
- 
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Table 2 continued. List of frequently used instruments to measure subjective 
cognitive decline 
Name 
Year 
Country Features 
Participants 
assessed for  
instrument 
development 
Scale 
development 
Example 
studies 
SCCQ [67] 
2006 
Australia 
 
60 items 
multi- 
domain 
Healthy volunteers Experts 
(unclear) 
- 
ECog [57] 
2008 
USA 
39 items, 
multi- 
domain 
Originally intended 
for informant 
reporting. Based on 
mixed 
clinical/population 
sample 
Survey of 
existing 
measures, 
literature 
review, 
experts 
ADNI [68] 
CDQ [69] 
2011 
Sweden 
 
20 items, 
multi- 
domain 
Community-based 
sample (Betula 
study) 
Experts, 
statistical 
analysis 
- 
SASCI-Q 
[70] 
2013 
Sweden 
 
45 items, 
multi- 
domain 
Memory clinic 
patients with SCD, 
healthy volunteers 
Patient 
interviews, 
experts 
Gothenburg 
MCI study 
[71] 
SCD-Q [72] 
2014 
Spain 
24 items, 
multi- 
domain 
Healthy volunteers, 
patients with SCD, 
MCI, dementia 
Survey of 
existing 
measures, 
literature 
review, 
experts 
Barcelona 
Memory 
clinic study 
[73] 
AAMI = age-associated memory impairment; ADNI = Alzheimer’s disease neuroimaging 
initiative; AMSTEL = Amsterdam study of the elderly; CDQ = cognitive dysfunction 
questionnaire; CFQ = Cognitive failures questionnaire; ECog = Everyday Cognition 
questionnaire; MAC-Q = Memory assessment complaint questionnaire; MFQ = Memory 
functioning questionnaire; PROCOG = Patient-reported outcomes in cognitive impairment 
questionnaire; SASCI-Q = Sahlgrenska academy self-reported cognitive impairment 
questionnaire; SCCQ = Subjective cognitive complaints questionnaire; SCD-Q = 
Subjective cognitive decline questionnaire; SMC scale = Subjective Memory Complaints 
scale 
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Many of the frequently used questionnaires were developed about 20-30 years 
ago. A general tendency for instruments developed in later years is that more 
specific clinical populations are targeted. There is also a tendency to widen the 
object of assessment from ‘memory’ to ‘cognition’, which is in line with 
current evidence that multiple cognitive domains, and not just memory, are 
affected also early on the dementia continuum [74]. Two questionnaires (other 
than the instrument presented in this thesis study I) has been developed or 
subsequently validated to assess differences between healthy controls and 
patients with SCD (the subjective memory complaints scale – SMC scale, and 
the subjective cognitive decline questionnaire - SCD-Q, both presented about 
concurrently with our instrument Sahlgrenska academy self-reported cognitive 
impairment questionnaire - SASCI-Q) [65, 70, 72]. Another recent study used 
advanced statistical methods, such as item response theory, to identify a subset 
of relevant SCD questions [75]. By this statistical approach, questions were 
grouped into other themes (e.g. global memory functioning and temporal 
comparisons) than the traditional cognitive domains [75]. 
 
2.6.2 SCD in different research settings 
A distinction needs to be made between SCD in community/general population 
contexts vs clinical contexts. Early studies (during 1990-2005) on subjective 
cognitive symptoms were often large population-based studies, whilst the 
proportion of clinically based studies have increased in publications that are 
more recent. In population-based studies, subjects may be assessed as ‘having 
SCD’ by their response to a question or questionnaire about cognition or 
memory, and are not active help-seekers, contrary to patients in clinical 
settings. This distinction was acknowledged already in early research [36] and 
was further elaborated by Stewart [45], who suggested that the term 
‘complaints’ therefore is more suitable for clinical research settings, and 
‘impairment’ for epidemiologic settings. The issue is especially relevant 
considering the high prevalence of subjective cognitive symptoms in 
population-based studies. Memory complaints severe enough to trigger help 
seeking are likely to be of higher clinical validity than ‘general comments’ 
referring to ‘poor memory’ in population-based populations [76]. This was 
supported by a study that observed that SCD was more ‘severe’ in patients who 
sought help at a memory clinic than in subjects with SCD identified in 
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population-based studies [65]. The prognosis of SCD may also differ – it has 
been observed that memory clinic patients have a higher risk of conversion to 
dementia [77, 78]. However, negative findings were also reported [79]. 
Although clinically based studies often include smaller samples compared with 
population-based studies, they generally present better-characterized patient 
groups, e.g. separating between SCD and MCI.  
Two important current studies – ADNI and AIBL - used mixed samples, 
consisting of both volunteers and memory clinic patients, which may be 
methodologically problematic [80]. The SCD-I group acknowledged sample 
differences and argued that “all SCD studies should explicitly describe their 
recruitment strategy and describe the setting” [46, 55]. Typical research 
settings include (1) population-based studies, (2) volunteer samples, and (3) 
medical help–seeking samples [46]. Epidemiological studies generally have 
larger samples, followed for longer time periods, compared to clinical studies, 
whilst clinical studies perform more detailed examinations [81], e.g. more 
frequently separating between SCD and MCI. More comprehensive test 
batteries are often used in clinical studies, thus the threshold for determining 
MCI is therefore likely lower in clinical settings [81]. 
Additionally, different paths to recruit ‘normal healthy controls’ or ‘healthy 
volunteers’ lead to sample differences. On average, persons volunteering 
through e.g. advertising or media appeals have higher education and are 
generally more well-functioning compared to controls randomly selected from 
the general population [82]. Having a family history of dementia is more 
frequent in volunteers compared to in the normal population [82]. This is not 
surprising, as individuals with a parent or sibling with dementia may be more 
motivated to contribute to dementia research. Thus, it should be noted that 
volunteering in a research study might mask an actual subjective cognitive 
concern, in some individuals. 
Taken together, these findings suggest that there are large variations based on 
type of research setting and sample in this research field, and the 
generalizability between clinical and epidemiological studies is limited.  
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2.7 SCD – confounders 
In this context, ‘confounders’ refers to variables - other than related 
to dementia - that may be associated with SCD. 
 
 
 
2.7.1 Depressive and anxious symptomatology 
Intuitively, an association between a negative appraisal of one’s own cognitive 
functioning and a lowered mood, such as depressive symptomatology, seems 
plausible. A depressive state leads to negative self-perception, which may lead 
to an increased overall tendency to report various kinds of problems. This 
association has been thoroughly explored by researchers, likely further 
motivated by that the many negative findings of associations between 
subjective and objective cognitive functioning increases the need for 
alternative hypotheses.   
The association between depressive symptomatology/feelings of anxiety, and 
SCD, has been widely supported in clinical as well as population-based studies 
[38, 39, 53, 83-87], most frequently focusing on subclinical affective 
symptoms. One large population-based study observed that this association 
was similar across different age groups throughout adulthood [88]. A memory 
clinic based study reported that young patients (< 65 years) with an affective 
disorder had the most subjective cognitive symptoms compared to other 
memory clinic groups (dementia, MCI, no cognitive impairment) [85]. Several 
studies, e.g. sub-studies from ADNI and AIBL, have reported findings 
suggesting that this association is stronger than the association between 
subjective and objective cognitive performance [68, 84, 89-91].  A ruminative 
style of thinking (the tendency to focus on negative emotions and their 
meaning), and a history of depression has been associated with SCD [92, 93]. 
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A study of the specific beliefs related to subjective cognitive symptoms 
observed that depressive symptomatology was more frequent in memory clinic 
patients who perceived cognitive symptoms to have serious consequences and 
who perceived a low personal control over the symptoms [94]. In a 
continuation of that study, beliefs held about the symptoms were found to be 
stronger determinants of negative affect than coping strategy, or 
clinical/demographic factors [95].  
Overall, the close connection between negative affect and subjective cognitive 
symptoms is well established and hardly surprising. However, the 
directionality between negative affect and cognition is unclear and represents 
a classic ‘chicken-and-egg’ problem. What comes first? Depression is 
sometimes part of the prodromal stage of dementia and/or an independent risk 
factor of dementia. Recent findings summarized by Kessing [96] suggest that 
some forms of a depressive disorder, such as early-onset depression before 65 
years and a recurrent depression, may be long-term risk factors for subsequent 
dementia, whereas onset of more recent depressive symptoms may be part of 
a prodromal phase of dementia. Furthermore, depressive symptomatology is 
common in MCI [97], manifest dementia [98], especially in vascular dementia 
forms [99]. One study reported that in amyloid-positive healthy elderly, 
anxiety symptoms predicted cognitive decline [100]. The Leukoaraiosis and 
disability study (LADIS), a large clinical multicenter study on elderly persons 
with white matter changes, has reported associations between depressive 
symptoms and white matter changes in several cross-sectional studies [101-
103]. By using a longitudinal approach they could show support for that white 
matter changes are likely causal in the pathogenesis of late-life depression 
[104]. On the contrary, one study observed that SCD was more associated with 
psychological distress than with vascular risk factors [105].  
Results from our Oslo-based sister-study showed that depressive symptoms 
was common in a small sample of memory clinic patients (40% prevalence) 
[106]. However, the authors could not establish a significant association 
between depressive symptoms and AD-type brain changes such as CSF 
abnormal concentrations and structural/functional brain imaging markers – in 
neither SCD nor MCI patients [106]. Reports from the AIBL study showed that 
otherwise healthy volunteers with high scores on a measure of subjective 
cognitive symptoms exhibited significantly more depressive symptomatology 
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than those with low scores [53]. The results were especially pronounced for 
persons with non-pathological Aβ [53].  
Despite the convincing associations between SCD and affective factors, it is 
important to note that reporting subjective cognitive symptoms may be entirely 
unrelated to both negative affect and disease progression, given the high 
prevalence of SCD in the normal aging population.  Thus, the relation between 
negative affect and cognitive dysfunction – objective as well as subjective - is 
complex. 
 
2.7.2 Psychosocial stress 
‘Stress’ is a vague term that can be used to describe a range of phenomena – 
relating to physical, biological as well as psychological mechanisms. It may be 
defined as ‘a state of mental or emotional strain or tension resulting from 
adverse or demanding life circumstances’ [107]. There are also related 
concepts describing more severe states such as ‘stress-related exhaustion’, or 
the previously popular but unfortunate term ‘burnout’. Both terms may be 
defined as a work-related chronic stress syndrome combining emotional 
exhaustion, depersonalization, and reduced personal accomplishment [108]. In 
ICD-10, stress-related exhaustion is diagnosed by code F43.8A 
(‘utmattningssyndrom’) [3]. The symptoms and signs of stress-related 
exhaustion overlap with depression and anxiety, but it has also been 
distinguished as a unique concept [109].  
In this thesis, we use the term ‘psychosocial stress’. ‘Psychosocial’ means 
‘relating to the interrelation of social factors and individual thought and 
behaviour’ [110]. ‘Psychosocial stress’ is per definition related to life events 
or conditions, whilst depression may be unrelated to external events. In simple 
terms, a person experiencing severe stress is primarily overwhelmed, whilst a 
person with depression has a low mood and a person with anxiety experiences 
fear and worry.  
Cognitive dysfunction is one of the key symptoms of stress-related exhaustion. 
However, psychosocial stress in relation to SCD in older adults has been the 
focus of few studies, compared to the large amount of studies on e.g. SCD and 
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depressive symptoms. Studies on patients with stress conditions have 
identified frequent subjective [111] as well as objective [112] cognitive 
impairment.  One study reported that the frequency of subjective cognitive 
impairment was considerable, although objective cognitive impairments were 
only mild, in patients with work-stress induced exhaustion [113]. Considering 
objective cognitive impairment, studies have reported that decline in attention 
and memory [114, 115] as well as executive functions [116, 117] may be 
characteristics of stress-related exhaustion. Population-based studies have 
reported associations between perceived stress and SCD [105, 118], also 
independent of influences of depression and anxiety [119]. Stress conditions 
are associated with higher cortisol levels and hypothalamic-pituitary-adrenal 
axis dysfunction, which has also been observed as a characteristic of patients 
with SCD [120]. Very few studies exist on stress and SCD in memory clinic 
samples. A Swedish study reported a 71 % prevalence of psychosocial stress 
in SCD patients, defined as self-reported daily stress over the last 3 months, 
compared to 18 % in patients with MCI [39].   
 
2.7.3 Somatic and other conditions 
SCD has been reported in a large number of somatic and other conditions, such 
as traumatic brain injury, epilepsy, bipolar disease, menopause, Parkinson’s 
disease, multiple sclerosis and cancer - just to mention a few that were 
summarized by Stewart [45]. A comprehensive range of conditions related to 
cognitive impairment is further accounted for in the text-book Kognitiv 
Medicin [121]. Besides clinical conditions, SCD has also been identified 
following different treatment interventions such as chemotherapy and radiation 
treatment in cancer [122], coronary artery bypass graft surgery [123] and 
electroconvulsive therapy [124].  
 
2.7.4 Demographic factors 
SCD is common throughout life. A large community-based study reported a 
29 % prevalence of SCD in younger adults and 52 % in older adults [125]. Not 
surprisingly, the prevalence of SCD increases with age [37], although some 
 45 
 
have not been able to corroborate these findings [126]. Normal aging is 
associated with some decline in cognitive functioning and therefore a certain 
presence of SCD is expected in healthy older adults. Consequently, population-
based studies have found that the prevalence of SCD in older healthy adults is 
high - between 25 and 50 % [36]. How SCD is perceived by older adults is for 
example reflected by the rate of help-seeking, which is low (refer to details 
below, in the section on Help-seeking) and may suggest that subtle cognitive 
changes may be perceived as a part of normal aging by most otherwise healthy 
individuals. SCD has also been associated with lower educational attainment 
in population-based samples [37]. Considering sex, Holmen [37] found no 
clear differences between men and women, although men in the normal 
population reported slightly more difficulties. 
 
2.7.5 Personality traits 
Personality characteristics related to SCD in the absence of objective cognitive 
decline includes high neuroticism, low feelings of mastery and a low level of 
perceived self-efficacy [127]. High levels of neuroticism in SCD were also 
supported by a Swedish study [128], but only for female participants. 
Furthermore, females with SCD reported higher levels of agreeableness and 
lower scores on extraversion compared to a normal population sample. 
Another Swedish study [129] investigated differences in personality between 
memory clinic patients with MCI, SCD and healthy controls. SCD and MCI 
patients scored higher than controls on anxiety proneness and aggression-
hostility, and lower on traits of extraversion. Conscientiousness is another 
personality trait that has been observed to influence SCD [130], suggesting that 
persons who are more “organized, achievement-striving and dutiful” are more 
likely to report and seek help for their SCD. Obviously, the ‘chicken-and-egg’-
problem is worth regarding also for the relationship between personality traits 
and SCD. Behavioral changes secondary to cognitive symptoms rather than 
corresponding to personality traits established previously in life, may very well 
affect how individuals score on personality questionnaires.  
 
46 
 
2.7.6 Awareness in relation to SCD and MCI 
Awareness may be defined as the ability to accurately appraise aspects of one’s 
own situation or functioning. In this context, awareness refers to whether self-
reported cognitive symptoms accurately reflect the actual cognitive level. 
‘Metacognition’, ‘metamemory’ and ‘insight’ are related terms, often used 
interchangeably in studies [131]. ‘Anosognosia’ generally refers to a more 
clinically noticeable form of impaired awareness, and is part of the more 
advanced dementia syndrome. Cognitive experimental studies often use 
standardized tests such as ‘Judgment of learning’ or ‘Feeling of knowing’, to 
investigate ‘meta-cognition’ [132] (which is the preferred term in experimental 
settings). In clinical settings, a common measure of awareness is to compare 
self-report with reports of functioning from an informant [132].  
Cognitive awareness is a key issue on the borderline between subjective and 
objective cognitive decline. It is especially important in dementia research as 
awareness of cognitive functioning eventually decreases in patients with a 
dementia disorder. The degree of awareness has been increasingly studied 
lately [131], also in incipient stages of dementia such as MCI. The concept of 
MCI is well used and rather well defined, but also highly heterogeneous 
potentially including individuals with very few objective signs of cognitive 
decline and those who are close to a dementia diagnosis. The uncertainty about 
the level of awareness in MCI patients is reflected in the ambiguous role of 
SCD in the MCI criteria. Initially, memory complaints were included in the 
‘Petersen criteria’ [23], but in revised criteria they were given a less prominent 
role as complaints should then be ‘corroborated by an informant’ [24]. One 
study found that about half of persons developing AD did not report problems 
with their memory three years before diagnosis [133] – i.e., when they were 
supposedly in an MCI phase. Based on such results, it has been suggested that 
memory complaints should be excluded altogether from the MCI criteria [134].  
Roberts et al. [131] reviewed 16 studies on the topic of degree of awareness of 
memory functioning in MCI patients, and addressed the question whether the 
degree of awareness in MCI may predict future progression to dementia. 
Unsurprisingly, given the heterogeneity of the MCI concept, the review by 
Roberts et al. concluded that people diagnosed with MCI differ in level of 
awareness. Whereas some patients with MCI have a low degree of awareness, 
but not at the level of dementia, others tend to over-estimate dysfunction [131]. 
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In the review, one study investigated ‘unawareness’ in MCI as a predictor of 
dementia, finding that under-reporting of functional decline compared to 
informant reports strongly predicted subsequent dementia (mean follow up 
time two years). Similar findings have been reported using ADNI data – 
underestimation of cognitive difficulties in patients with MCI was associated 
with positive AD biomarkers and progression to dementia [68]. 
Research concerning meta-cognition is a large separate research area, 
including numerous theoretical models and hypotheses about e.g. 
neuroanatomical correlates. A more detailed outline of this field is outside the 
scope of this thesis.  However, it should be noted that a compromised degree 
of accordance between actual and self-reported level of functioning is common 
also in the normal population, and it has been hypothesized that impairment or 
‘incompetence’ within an area leads to a diminished capacity to accurately 
appraise one’s ability [135]. Translated to memory functioning: if your 
memory is poor, you are more likely to forget what you have forgotten.  
 
2.7.7 Help seeking for cognitive symptoms 
The implications of subjective cognitive symptoms do not only rely on an 
individual’s identification of problems, but also on her decision and ability to 
seek medical help. Empirical investigations of the process or determinants of 
help seeking are not included in this thesis. However, to seek medical 
consultation is an important common characteristic of the otherwise 
heterogeneous memory clinic patient group. Scientific reports related to help 
seeking for cognitive symptoms are therefore briefly summarized below.   
How common is help seeking for subjective cognitive symptoms? A Danish 
survey showed that less than 20 % of elderly patients who considered their 
memory to be impaired had consulted a physician [136]. In a large Australian 
survey, 26% of respondents reporting memory complaints interfering with 
daily life had consulted a physician. When comparing help seeking patterns 
associated with seventeen different symptoms such as angina, asthma, hearing 
problems, headaches, insomnia etcetera, subjective memory impairment was 
the fifth most prevalent symptom - but the least likely symptom to trigger help 
seeking [137].  
48 
 
Why do some people with subjective cognitive symptoms choose to seek 
professional help, while others do not? Research findings show that the 
tendency to seek help seems to be more influenced by factors such as 
perceptions, knowledge and experience, than by actual risk factors for 
dementia. In a study comparing persons who sought help at a memory clinic 
with persons who did not seek help despite subjective cognitive symptoms, 
there was no significant difference in objective cognitive performance [138]. 
A large community-based study showed no significant difference regarding 
presence of the APOE ε4 genotype, between help seekers and non-help seekers 
[92], and pathological levels of Aβ42 were in another study not more prevalent 
in help seekers compared to non-help seekers [139]. Factors that have been 
associated with help seeking for subjective cognitive symptoms are: perceiving 
that one’s memory is worse than that of peers [138]; believing that the 
cognitive problems have a biological or medical cause [138, 140]; having a 
family history of dementia [138, 141, 142]; having good knowledge about 
dementia warning signs [143]; having poorer physical health [92]; being more 
concerned about the problems [140, 141]; having a good perception of medical 
services [140]; and experiencing more deterioration in daily functioning and 
lower quality of life [142]. The relationship between depressive/anxious 
symptomatology and help-seeking is not clear, as both positive [65] and 
negative associations [138, 142] have been reported.   
To not seek help despite of subjective cognitive symptoms, or only seeking 
advice in informal settings (e.g. friends or family, internet), has been associated 
with perceiving memory problems to be caused by non-biological factors, not 
amenable to medical treatment [138]. Other studies have reported that socio-
economic barriers such as low educational attainment; belonging to an ethnic 
minority; and low income, are factors associated with lower frequency of help 
seeking [144]. Furthermore, better physical health [92]; having less concern 
about the problems; having poor perceptions of medical services; and believing 
that the cause of the problems are psychosocial (e.g. stress related) or a part of 
normal aging [140, 144], are other factors that have been associated with not 
seeking help. Additionally, there may be a cohort effect in that cognitive 
problems may be more accepted by older individuals as a ‘normal’ part of 
aging, and therefore are tolerated for a longer time before seeking help [143]. 
The health belief model (HBM) can be applied to better understand the process 
of help seeking [145]. The model suggests that people's tendency to seek help 
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stems from several factors, such as how serious they perceive the health threat 
to be, what the benefits and barriers are to seeking help, and how susceptible 
to actual disease they assess themselves to be [145, 146]. In Figures 5 and 6, 
the HBM is applied to illustrate the process of help seeking vs non-help seeking 
for cognitive symptoms, based on previous research findings.  
Similarly, the ‘common sense model of illness perception’ [147] deals with 
how people respond when they experience health problems. According to this 
model, people develop different coping strategies based on their beliefs and 
knowledge about e.g. the cause of the symptom, the consequences of the 
symptom, controllability of the symptom, and likely future duration of the 
symptom. The model has been used in the context of SCD [95], MCI [148] and 
dementia [149]. 
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Figure 5. The health belief model, modified to exemplify possible factors leading to 
increased help seeking tendencies for subjective cognitive symptoms.  
 
 
Perceived 
threat 
Cues to action 
“I know where to seek help. 
My family is telling me to 
seek help. My problems 
affect me a lot and this 
motivates me to seek help.” 
Modifying variables  
“I worry about my health. 
I have knowledge about 
dementia and which signs 
to look for. I generally 
seek medical care when I 
have a medical problem.”  
Perceived seriousness 
“Dementia is not just a 
normal part of getting 
older, it is a brain disease. 
All aspects of my life will 
be affected if I have the 
disease.” 
 
Perceived benefits vs 
perceived barriers 
“Maybe there are new 
treatment options. Even if 
there is no cure, my family 
and I can receive support and 
information. It is better to 
know. I generally trust 
medical services.” 
High 
likelihood of 
seeking help 
from medical 
services 
Perceived susceptibility 
“Dementia is common and 
may very well happen to 
me. Several of my family 
members had dementia.” 
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Figure 6. The health belief model, modified to exemplify possible factors 
leading to decreased help seeking tendencies for subjective cognitive symptoms. 
 
 
Perceived 
threat 
Cues to action 
“I don’t know where to seek 
help. No one is telling me to 
seek help. My problems 
don’t affect my everyday life 
that much.” 
 
Modifying variables  
“I’m not a worrying type 
of person. I don’t know 
much about what dementia 
is and what signs to look 
for.”  
 
Perceived seriousness 
“My problems are just a 
normal part of getting 
older. My problems are not 
very serious; probably they 
won’t get worse. It is 
probably just stress.” 
 
Perceived benefits vs perceived 
barriers 
“There is no cure anyway. I feel 
ashamed to talk about these 
problems. It is better not to know. I 
generally have a low confidence in 
medical services.” 
Low 
likelihood of 
seeking help 
from medical 
services 
Perceived susceptibility 
“Dementia won’t happen 
to me. No one in my family 
has had dementia. I’m too 
young to get dementia” 
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2.8 Associations with dementia and related 
factors 
 
 
 
This research area addresses the key question about the relationship between 
SCD and dementia, and involves several different lines of research. Since far 
from everyone with SCD will develop MCI and dementia, identifying features 
that are more associated with deterioration over time than others is an essential 
issue. This issue is approached by cross-sectional investigations associating 
SCD with other dementia-related factors such as brain and neurochemical 
changes, objective cognitive performance and functional level; as well as 
longitudinal studies of cognitive changes and development of dementia.  
 
2.8.1 Objective measures of cognition in relation to 
SCD 
‘Objective’ measures of cognition commonly refers to assessment using 
neuropsychological tests – i.e. measuring cognitive ‘signs’. Sometimes the 
term ‘cognitive tests’ is used, usually when describing a briefer assessment. 
Informant-reported cognitive decline is occasionally also categorized as an 
‘objective’ measure, in the regard that it indicates signs rather than symptoms.  
Neuropsychological tests are standardized tests developed to assess cognitive 
functions and dysfunctions, which may be linked to central nervous system 
disease or injury. Cognitive functions are divided into cognitive ‘domains’, 
such as the memory/learning-, attention-, language-, visuospatial- and 
executive domain. The borderline between domains and associated tests vary 
greatly throughout the literature. Validity and reliability are important 
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psychometric aspects of neuropsychological test development. In short, a test 
is valid if it successfully measures what it is intended to measure and reliable 
if it produces similar results under consistent conditions. Most of the more 
prominent neuropsychological tests have been used and further developed for 
decades, adding to their robustness. The associations between tests and 
different neurological conditions are generally well established by numerous 
studies. Nonetheless, the ‘objectivity’ of any test may certainly be discussed – 
the term ‘objective’ is however frequently used in this field of research as a 
natural counterpart to ‘subjective’. Alternatively, in this thesis 
objective/subjective is sometimes replaced with ‘detectable’/’not detectable’ 
or ‘test-measured’/’self-reported’.  
As an assessment of validity of the SCD concept, several studies have 
addressed the relation between SCD and objectively measured cognitive 
performance, as measured with neuropsychological tests. To assess the 
‘validity of SCD’ by comparing self-report to test results may be discussed, as 
it may be argued that, per definition, only the patient affected by the symptoms 
can validate her own symptom-status. Symptoms are just symptoms – if they 
can be verified by tests, they should rather be referred to as signs. Nevertheless, 
it is certainly of interest to investigate the associations between symptom-
assessment and test-measured cognitive performance. In general, studies have 
reported that the associations between subjective and objective cognitive 
functioning have often been weak or non-existing [84, 86, 91, 150-152]. 
However, a few positive correlations have also been reported [153-155].  
Reports from the AIBL study concluded that patients with objective cognitive 
impairment (MCI) reported more subjective cognitive symptoms compared to 
healthy controls, but there was generally no association between subjective 
cognitive symptoms and memory tests [84]. Similar findings were reported 
using ADNI data – there were no associations between subjective cognitive 
symptoms (measured with ECog) and a battery of six well-established 
neuropsychological tests [68]. Another study investigated the association with 
objective cognitive performance and specific items from several SCD 
questionnaires. They found that age-anchored questions (asking the respondent 
to compare with peers of the same age) reflected objective performance the 
most accurately [156]. In contradiction, a large population-based study 
reported findings that supported an association between subjective and 
objective cognitive functioning [153]. They also analyzed specific subjective 
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cognitive symptoms, finding that some symptoms (e.g. ‘difficulties finding 
one’s way around familiar streets’ and ‘difficulties following group 
conversations’) were more associated with objective cognitive difficulties than 
others (e.g. ‘forgetting things from one second to the next’) [153].  
Informant report refers to an assessment by a close family member or friend 
regarding an individual’s level of functioning. As signs may present later than 
symptoms in the disease process, it may not be surprising that several studies 
have found that informant report is a better predictor of concurrent objective 
cognitive performance than self-report. e.g., [47, 86, 157-159]. Similar to the 
methods available for self-report of cognitive decline, there are numerous 
instrument used for informant-reported cognitive decline [160]. The perhaps 
most wide-spread instrument is the Informant questionnaire on cognitive 
decline in the elderly (IQCODE), asking the informant to rate the participants’ 
function compared to previously [161]. Our group co-developed the Cognitive 
Impairment Questionnaire (CIMP-QUEST), an informant-report instrument 
designed to identify dementia signs related to different brain regions [162]. 
 
2.8.2 Brain changes and imaging markers in SCD 
Brain changes related to dementia include both anatomical and functional 
changes, involving e.g. reduced volume of structures important for the forming 
of memory such as hippocampus; abnormal glucose metabolism in related 
brain areas; and changes in activation patterns measured when performing 
cognitive tasks. Several brain changes related to dementia have also been 
associated with SCD. Evidence of morphological, functional as well as 
metabolic changes have been observed in clinical as well as in population-
based settings. More specifically, SCD has been associated with decreased 
volume of the hippocampus [163-165] and entorhinal cortex [163]; decreased 
grey matter in other areas of the medial temporal lobe and frontotemporal 
regions [166]; white matter lesions in the temporal region [164] and in the 
subcortical parieto-occipital area [167]; changes in glucose metabolism in 
parieto-temporal regions, especially the medial temporal lobe involving 
hippocampal and parahippocampal areas as well as precuneus [165, 168]; and 
reduced right hippocampal activation during an episodic memory task [169]. 
Brain activation patterns have been found to be similar in SCD and MCI 
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patients [170] as well as in SCD and AD patients, such as changed activation 
in the left medial temporal lobe, bilateral thalamus, posterior cingulate and 
caudate [171]. Magnetoencephalography studies have found differences in the 
neurophysiological profiles of SCD patients compared to healthy controls 
[170, 172]. 
However, negative findings have also been reported. One population-based 
study did not find any difference in hippocampal or amygdala volumes 
between persons with vs without SCD [92], and another study could not 
confirm any association between SCD and severity of white matter 
hyperintensities [173].  
 
2.8.3 SCD and neurochemical biomarkers for AD 
The three most well-established neurochemical biomarkers for AD are the 42 
amino acid form of amyloid-β (Aβ42), total tau (t-tau) and phosphorylated tau 
(p-tau). The ‘amyloid cascade hypothesis’ was postulated in 1991/1992, 
suggesting that Aβ is the driving mechanism of AD, via a defective cleavage 
of the amyloid precursor protein (APP) [174, 175]. When Aβ is defectively 
released from APP, it aggregates into ‘plaques’, which is one of the two 
hallmark pathologies of AD and leads to neuron death [176]. Aβ is increased 
in both familial and sporadic forms of AD. When Aβ aggregates into plaques, 
the concentration of Aβ in the CSF decreases, resulting in that lower levels of 
CSF Aβ are associated with higher risk for AD dementia. Aβ deposition may 
also be measured by PET imaging [177].  
Tau markers are associated with the second hallmark pathology of AD – 
neurofibrillary tangles [178]. This pathology relates to the defective contact 
between neurons – loss of synapses. The normal function of tau protein is to 
stabilize the microtubules – the transport pathways – of the neuronal axons. In 
AD, this function has deteriorated, causing damage to the axons. Tau proteins 
that are failing to bind to the microtubule are believed to clump together, 
forming neurofibrillary tangles [179]. P-tau is the phosphorylated form of tau 
[180]. The tau markers are described as markers for brain damage, more 
specifically indicating axonal degeneration [181]. When tau is pathological, 
the concentrations in CSF t-tau and p-tau are elevated. A combination of 
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decreased levels of Aβ42 and increased levels of t-tau and p-tau, are sometimes 
described as a “CSF AD profile”, e.g. [182]. Using a metaphor derived from 
the amyloid cascade hypothesis, Aβ can be described as the trigger of AD, and 
tau as the bullet – causing the damage but not acting independently from the 
trigger [183].  
The association between Aβ, tau and AD dementia is however not that clear-
cut. Significant levels of Aβ plaques have been found in the absence of 
symptoms [50, 51]. The prevalence of amyloid plaques has been observed to 
increase with age regardless of diagnosis [184]. Tau – being a marker for brain 
damage – is not specific for AD and is abnormal in more than 20 clinico-
pathological entities [185].  
The reported prevalence of pathological AD biomarkers in SCD vary across 
studies, which in part is related to use of different cut-offs and ratios to 
determine pathological levels. A memory clinic based study reported that 
prevalence of pathological CSF concentrations in SCD patients was 24%, 32% 
and 21% for Aβ42, t-tau and p-tau respectively, and 7% for a combined CSF 
AD profile [186]. From the memory clinic multicenter DESCRIPA study 
[187], it was reported that a CSF AD profile, based on an Aβ:tau ratio, was 
present in 52% of SCD patients, which was significantly more frequent 
compared to healthy controls (31%). A clinical study based on a small sample 
found no statistically significant differences in the three CSF AD biomarkers 
between subjects with and without SCD [188]. 
The AD CSF biomarkers have mostly been used to identify AD pathology 
during the MCI stage [182]. However, cross-sectional studies on CSF markers 
in SCD patients, and comparing SCD and MCI patients, are rapidly emerging. 
It would be especially interesting if an exponential increase from healthy older 
adults, to SCD, MCI and AD dementia could be established. A recent review 
[1] of 36 studies on the subject of Aβ and tau markers and their associations 
with SCD reported that some studies have reported significant biomarker 
concentration differences between SCD and MCI, whilst others reported 
negative findings. Overall, more studies reported differences between SCD and 
MCI considering Aβ (i.e. individuals with SCD had less pathological Aβ 
concentrations compared to individuals with MCI) than considering tau 
markers. Ten studies found no significant differences in t-tau and p-tau 
markers between SCD and MCI [1]. This result is unexpected, as it does not 
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correspond well with the suggested temporal order of AD, placing the presence 
of abnormal tau concentrations more closely in time to the onset of objective 
cognitive deficits compared to Aβ concentrations, which is believed to reach 
abnormal levels earlier. Few studies found a difference between SCD and 
healthy controls [1]. Nevertheless, Colijn and Grossberg concluded that there 
is some evidence from several studies of an exponential increase of abnormal 
Aβ and tau from SCD to MCI to AD dementia [1].  
In a study based on ADNI data, SCD was not analyzed as a separate group, but 
the presence of subjective cognitive symptoms in a subgroup of the MCI cohort 
was investigated in relation to CSF AD biomarkers. MCI patients with positive 
CSF AD biomarkers tended to underestimate their cognitive difficulties 
compared to MCI patients with negative CSF AD biomarkers. The risk of 
misclassification is therefore high when using subjective cognitive symptoms, 
according to the authors [68]. The AIBL study [84] investigated subjective 
cognitive symptoms as a continuous variable in a mixed sample of volunteers 
and MCI patients, in relation to e.g. amyloid burden. They could not establish 
a direct association between subjective cognitive symptoms and AD 
biomarkers. However, they observed that subjective cognitive symptoms were 
related to mood in healthy volunteers and correlated positively to age in MCI 
patients [84]. 
One study showed that having more subjective cognitive symptoms was 
associated with pathological concentrations of Aβ42 in healthy community-
recruited controls, while the reversed pattern was observed in MCI – less SCD 
was associated with pathological Aβ [189]. Using PiB-PET (Pittsburgh 
compound B, a PET method to measure beta-amyloid plaques in neuronal 
tissue), one study reported an association between Aβ burden and memory-
related as well as executive-related subjective symptoms, although an 
association between neuropsychological test measures and amyloid burden 
could not be found [190]. Another PiB-PET study [191] showed similar results 
for a group of 48 cognitively normal older individuals. Subjects with a higher 
Aβ load tended to be less confident about their memory abilities than those 
with a lower Aβ load, although these were not ‘complainers’ but were taken 
from a normal community sample. Studies have shown that presence of SCD 
in patients with a high Aβ burden predicts faster cognitive decline [53, 100].  
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To summarize, the associations between SCD and concentrations of Aβ or tau 
markers in older adults without detectable cognitive impairment are not clear. 
There is some evidence of an exponential increase of abnormal biomarker 
concentrations from SCD to MCI to AD dementia, but less evidence of 
biomarker differences between SCD and healthy older adults. Findings are 
mixed, and several findings have been negative. SCD is considered a largely 
heterogeneous group, which likely affects the possibility of finding positive 
associations between SCD and AD biomarkers.   
 
2.8.4 Prevalence of ApoE ε4 in SCD 
For the most common form of dementia – late onset AD dementia – the ε4 
variant of the gene coding for APOE is a well-known risk factor, possibly due 
to reduced neural protection and repair mechanisms which may lead to 
increased Aβ-deposition [168]. A memory clinic based study reported that the 
prevalence of the APOE ε4 genotype was similar in SCD patients (33%) as 
compared to MCI patients (32%) [186], and a second memory clinic study also 
reported non-significant differences in APOE ε4 prevalence between SCD and 
MCI [192]. Combining APOE status with amyloid/tau markers may increase 
the ability to predict AD dementia in patients with SCD [1]. Several recent 
studies have reported associations between amyloid/tau markers of AD and 
presence of APOE ε4 [168, 184, 187, 193, 194]. 
 
2.8.5 Subjective cognitive decline - longitudinal 
findings 
Are patients with subjective cognitive symptoms at greater risk of developing 
dementia? This is a key issue of the SCD research field. From 1995 to 2007, 
several large community-based studies investigated the ability of subjective 
cognitive symptoms to predict cognitive decline (defined as declining test 
performances or conversion to dementia) among elderly people [64, 87, 133, 
195-206]. Some reported positive associations [64, 87, 133, 195, 196, 200, 203, 
206], whereas others reported negative findings [197, 199, 202, 205], and in a 
few studies findings were mixed, e.g. results changed when adjusting for 
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objective cognitive level at baseline [198, 201, 204]. In these early days of the 
SCD research field, the importance of excluding subjects with detectable 
cognitive impairment to investigate SCD as a separate entity, had not yet been 
fully emphasized. Thus, only four of the 15 community-based studies 
mentioned above excluded MCI or a similar category [87, 198, 201, 204]. 
Various methods were used to measure subjective cognitive symptoms; most 
frequently, participants were asked a single question about memory problems. 
Follow-up time of the 14 studies ranged from one to nine years, with a mean 
of 4.5 years, and the mean number of participants was over 1.800.  
The hypothesis presented by Reisberg in 1986 [28] – that a phase characterized 
by subjective cognitive symptoms would last approximately 15 years before 
onset of MCI – was supported by a study in 2006 [207], in which patients were 
followed for 8.9 years. Based on the 15-year-hypothesis this would lead to a 
59.3% MCI development rate. The observed rate was 61.4%, thus quite close 
to the estimated progression rate. In a review [208], Reid and MacLullich 
summarized findings from community-based studies conducted prior to 2006, 
and concluded that there were increasing evidence of subjective cognitive 
symptoms predicting subsequent cognitive decline and dementia. However, 
the mix of subjectively and objectively impaired samples and other 
methodological variations between studies made it difficult to draw firm 
conclusions.  
A meta-analysis [79] including and comparing data from 32 community- and 
clinically based prospective longitudinal SCD studies, reported an annual 
conversion rate for individuals with SCD to dementia of 2.3 %, compared to 1 
% for subjects without SCD, thus representing a twofold increase in risk of 
dementia when SCD is present. The cumulative proportion of individuals 
converting from SCD to dementia over approximately 5 years was 11%. The 
annual conversion rate to MCI was 6.7%, and the cumulative proportion of 
converters was 24.4%. The authors concluded that SCD is a clinically 
meaningful indicator of subsequent cognitive decline [79].  
During the last decade, the number of clinically based longitudinal studies on 
SCD has increased. Studies range from large multicenter initiatives such as 
ADNI [68, 209], AIBL [53], DESCRIPA [187] and LADIS [210], to single 
center studies [39, 165, 211-217].  
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Elfgren et al. [39] concluded that the risk of SCD patients in their Swedish 
memory clinic sample (n=24) to develop MCI was small over 3 years, as 88% 
remained stable.  A study based on a British memory clinic sample [211] 
followed 62 SCD patients over a mean of 3.7 years, observing that 24% 
declined to amnestic MCI or dementia during that time. Additionally, being 
over 61 years of age when seeking help, and onset of SCD at later age, were 
strong predictors of decline. Declining SCD patients had lower scores on 
cognitive tests at baseline compared to non-decliners, even though they were 
within normal limits. A South Korean study followed 129 SCD patients over 
0.5-4.7 years, and reported that 22% declined to MCI or dementia during the 
study period. Higher age, lower cognitive scores at baseline, and being an 
APOE ε4 carrier predicted decline [217]. A Spanish study following 55 SCD 
patients reported that 25% declined to MCI or dementia over a mean follow-
up time of 3 years. Only three subjects declined to dementia – all three had 
abnormal CSF AD biomarker ratios [216]. In a Portuguese study, not excluding 
detectable cognitive impairment in subjectively affected individuals, 37% of 
134 patients with subjective cognitive symptoms developed dementia over the 
follow-up of at least 2 years [215]. This study also analyzed specific cognitive 
symptoms using the SMC scale, and reported that patients who did not convert 
actually reported more difficulties on several items (using notes; having 
difficulties finding words). Converters had fewer years of education, but age 
or depressive symptomatology did not differ between converters and non-
converters [215]. In a German study [165], 27 SCD patients were followed for 
3 years and were also examined using measures of glucose metabolism and 
MRI at baseline. SCD patients showed greater decline in episodic memory 
functions compared to healthy controls, but not in executive and speed 
functions. Weak associations were observed between longitudinal decline and 
brain imaging findings in this study.  
SCD has almost exclusively been studied in relation to AD dementia, however 
a few longitudinal studies have also used VaD as an outcome. For example, 
one study reported that SCD predicted AD dementia but not VaD [218], 
However, it should be noted that this study did not base the diagnosis of 
vascular dementia on neuroimaging findings. In the European LADIS study, 
SCD was observed to predict AD dementia as well as AD with a vascular 
component (small vessel disease) [210].  
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Longitudinal studies including CSF AD biomarkers generally show that 
abnormal levels of Aβ and tau markers in individuals with SCD are associated 
with an increased risk of future cognitive decline [1]. In a study from our group 
(the Gothenburg MCI cohort), the ability of CSF AD biomarkers to predict 
cognitive decline in specific cognitive domains from baseline to 2-year follow-
up was analysed for e.g. patients categorized as SCD [213]. It was observed 
that in SCD patients, t-tau predicted a significant proportion of the decline in 
the speed/executive functions domain, whilst Aβ was not significantly 
associated with any cognitive decline. In a study based partly on the same 
sample as the current thesis and pooled with a sister-sample from Oslo, t-tau 
rather than Aβ was associated with decline in memory over time in patients 
with SCD [214]. Autopsy studies have observed that subjective cognitive 
decline during the years prior to death can predict a neuropathological 
diagnosis of AD (plaques and tangles) in elderly persons with and without 
dementia during life [92, 219].   
 
2.8.6 Foundation of thesis aims 
Subjective cognitive decline is a possible early indicator of actual cognitive 
impairment and dementia, and is an inevitable aspect of the everyday clinical 
considerations regarding which patients are in need of further examination. If 
a firm association between SCD and subsequent dementia could be established, 
SCD has the potential to be useful in the early detection of neurodegenerative 
disease and thereby optimizing early interventions and treatment trials. SCD 
is, however, an elusive concept since it may reflect a pathological condition as 
well as normal aging. It may be affected by various aspects such as mood 
disorders, tendency to seek medical care and certain personality traits. SCD is, 
by definition, a subjective measure – but one that clinicians will have to assess 
and respond to when meeting the patient. Consensus definitions and criteria 
are emerging, but they are still ‘in the bud’, in need of evaluation.  
When establishing the aims of this thesis, some aspects of SCD research areas 
in need of further contributions were identified. Firstly, there has been a lack 
of comprehensive instruments specifically developed to measure a broad 
spectrum of SCD. Many instruments might be outdated and are not based on 
actual patient report. When starting out this project, there were no instruments 
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covering a broad range of cognitive domains, based on patient input and 
developed with the specific population in mind. Type and frequency of SCD 
has not been measured in most studies as often just a single question has been 
used to identify and investigate SCD. Memory has often been the only assessed 
cognitive domain.  
Secondly, the study of affective conditions in relation to SCD has mostly 
focused on depressive symptoms while aspects of stress are rarely studied. 
Clinical experience tells us that severe stress is not uncommon in this patient 
group and should be further studied.  
Furthermore, SCD in combination with biomarkers is a natural focus point of 
study, since both might identify phases prior to detectable cognitive signs. 
Brain imaging studies on SCD patients are quite frequent but there are fewer 
studies of CSF AD markers in SCD, especially including longitudinal follow-
up. Recent criteria for SCD and preclinical AD should be further evaluated.    
Finally, there are now several longitudinal studies investigating how patients 
with SCD progress or not over time. However, as this is the core question of a 
research field complicated by heterogeneous etiologies and methodological 
disparities, more studies are needed – especially in memory clinic samples with 
comprehensive measures and long follow-up time. Indeed, very few studies 
have focused on specific SCD symptoms and their relation to progression in 
comprehensively investigated individuals.  
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3 AIMS 
The general objective of this thesis is to investigate SCD in memory clinic 
patients with respect to characteristics and clinical relevance. ‘Characteristics’ 
refers to features that may characterize patients with SCD, and to the specific 
type of symptoms patients with SCD report. ‘Clinical relevance’ in this context 
refers to the degree of association between SCD and cognitive decline and 
dementia – the predictive ability of the concept. Considering the overview of 
SCD research (Figure 2), the separate studies included in the current thesis are 
related to ‘concept development’ (study III); ‘method development’ (study I), 
‘confounders’ (study II-IV), and ‘associations with dementia’ (studies III-IV). 
The term ‘SCI’ is used instead of ‘SCD’ in studies I-II, but in the following 
overall description of the studies, only ‘SCD’ will be used.  
Aim study I: To develop a patient-based comprehensive questionnaire on 
everyday cognition, with the ability to distinguish patients with subjective, but 
not objective, cognitive impairment seeking care at a memory clinic, from 
healthy controls. Furthermore, to examine the cognitive spectrum of subjective 
cognitive symptoms in patients with SCD.  
Aim study II: To investigate the prevalence of stress, depressive symptoms and 
CSF AD profiles in memory clinic patients categorized as SCD and MCI.         
Aim study III: To examine SCD, SCDplus, SCDplusbio (i.e. SCDplus + APOE 
ε4 and biomarkers), NIA-AA stages 0-3 of ‘preclinical AD’ and MCI in 
patients seeking care at a memory clinic, with respect to: 
1) the proportion of cognitively stable and declining patients 
over time 
2) the ability of the classifications to predict cognitive decline, 
dementia and AD dementia specifically 
3) the individual contribution of each feature included in the 
classifications to predict cognitive decline and dementia 
Aim study IV: To investigate potential differences in baseline subjective 
cognitive symptoms between progressing and non-progressing patients, 
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addressing possible explanatory variables such as CSF AD biomarkers and 
anxiety/depressive symptoms. Furthermore, to investigate differences in 
baseline subjective cognitive symptoms in MCI and SCD patients, in relation 
to cognitive outcome and CSF AD biomarkers, as an assessment of awareness 
in different cognitive stages. 
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4 PATIENTS AND METHODS 
 
4.1 Participants 
All participants were help seeking patients or healthy controls at the 
Sahlgrenska memory clinic, Gothenburg, Sweden. All studies included 
patients and healthy controls who had been previously included in the 
Gothenburg MCI study [71].  
Study I and IV, dealing with data from SASCI-Q, also included an additional 
sample of other memory clinic patients (‘the SASCI-Q-cohort’). 
Inclusion/exclusion criteria were identical, but some patients could accept 
participation in the shorter current study (which only entailed completing a 
questionnaire), but declined participation in the more comprehensive 
Gothenburg MCI study. In general, patients in the SASCI-Q-cohort completed 
similar examinations, but for analyses, data were collected from medical 
records and not from a previous study database. 
Inclusion criteria were: age 40-79 years and subjective or informant-reported 
cognitive decline with a duration of at least 6 months, established through 
clinical interview. Healthy controls were mainly recruited from senior citizen 
organizations and information meetings about dementia. They were assessed 
by a physician and included if they had no subjective or objective cognitive 
impairment.   
Exclusion criteria for all participants were: current severe somatic disease; 
current severe psychiatric disorder defined using DSM-IV criteria [220]; and 
current substance abuse or dependence defined using DSM-IV criteria [220]. 
In this thesis, patients were also excluded if they had manifest dementia at 
baseline.  
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Table 2. Brief summary of methods in study I-IV 
 Study I Study II Study III Study IV 
Time period for data 
collection 
2007-2010 2001-2011  1999-2013 2007-2016 
Sample origin 
Gothenburg MCI 
study cohort + 
SASCI-Q cohort 
Gothenburg 
MCI study 
cohort 
Gothenburg 
MCI study 
cohort 
Gothenburg MCI 
study cohort + 
SASCI-Q cohort 
Analysis design Cross-sectional Cross-sectional Follow-up Follow-up 
Key issue Method development Characteristics 
Criteria 
evaluation, 
prediction 
Characteristics, 
prediction 
Specific groups included SCD Healthy controls 
SCD 
MCI 
(Healthy 
controls) 
SCD 
Subtle cog. 
decline 
MCI 
(Healthy 
controls) 
SCD 
MCI 
(Healthy 
controls) 
 N total 143 353 336 245 
   N patients   93   250   235   130 
   N healthy controls   50   103   101   115 
Role of controls Included in main analysis 
To define 
normal range 
of NP scores 
To define 
normal range 
of NP scores 
To define normal 
range of NP 
scores 
Method to differentiate 
between SCD/MCI 
GDS 
 
 
GDS + 10 NP 
tests  
 
GDS + 4 AD 
specific NP 
tests  
 
GDS + 10 NP 
tests  
 
Main measurements included 
GDS X X X X 
SASCI-Q X   X 
NP tests  X X X 
CSF biomarkers  X X X 
Affective symptoms  X X X 
Reported stress (medical 
record review) 
 X   
Clinical interview (family 
history of dementia) 
 X   
APOE genotype   X  
APOE=apolipoprotein E; CSF=cerebrospinal fluid; GDS=global deterioration scale; 
NP=neuropsychological; SASCI-Q=Sahlgrenska academy self-reported cognitive impairment 
questionnaire. 
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4.2 Tests used to define SCD and MCI 
To make the distinction between SCD and MCI, different methods were used 
in the studies. Details are specified in Table 3. In short, in study I the Global 
deterioration scale (GDS) [22] was used, while in study II-IV, different sets of 
neuropsychological (NP) tests were used. GDS was also used in study II-IV, 
but only to exclude patients with no subjective/objective cognitive decline 
(GDS stage 1) or patients with probable dementia (GDS stage 4/4+). The 
developed SASCI-Q instrument (described in more detail in Study I Results) 
was thus not used to define a group with SCD, but was used to measure specific 
subjective cognitive symptoms. 
Other studies within the Gothenburg MCI study have generally used GDS, and 
not NP tests, as defining instrument for SCD (often called SCI) vs. MCI. The 
rational for this is to avoid circularity since NP tests have often been used as 
outcome measures. The GDS stages in the Gothenburg MCI study are 
determined by medical history, clinical assessment and four cognitive 
instruments: for assessment of basic cognitive symptoms such as memory 
disturbance, disorientation, reduced abstract thinking, visuospatial 
disturbance, poverty of language, sensory aphasia, visual agnosia and apraxia, 
Stepwise comparative status analysis (STEP; [221]) is used. For executive 
symptoms I-FLEX (a short form of the executive interview EXIT; [222]) is 
used. The assessment is further based on scores on the Mini-Mental State 
Examination (MMSE; [223]) and Clinical Dementia Rating sum of boxes 
(CDR; [224]). The GDS algorithm is presented in detail in study I and further 
in Wallin et al. 2016 [71], which offers a comprehensive account of methods 
used within the Gothenburg MCI study. GDS stage 1 means that no subjective 
or objective cognitive impairment is present. GDS stage 2 corresponds to what 
is often called ‘the SCI stage’ and is fulfilled if subjective cognitive complaints 
are present (determined through clinical interview) but only very subtle or no 
impairment detected by the GDS tests. GDS stage 3 corresponds to an ‘MCI 
stage’, and may include subjective cognitive complaints but more importantly 
is set based on that GDS tests reveal a cognitive impairment which is still mild 
but more impaired than expected. GDS stage 4 or more indicates probable 
dementia, and these patients are further assessed using standardized dementia 
criteria. Generally, the GDS staging procedure is clinically useful but less 
refined than an NP test battery. In other words, NP tests are more difficult than 
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cognitive screening tests. When SCD is defined as ‘GDS stage 2’, some 
patients who would have an impaired NP test profile may be included in the 
SCD group. When using NP tests, the exclusion of objective cognitive 
impairment in the SCD group is more rigorous and closer to what is used 
clinically in a comprehensive specialist investigation of early subtle signs of 
dementia. Nevertheless, both methods (and many others) are used in similar 
studies worldwide.  
GDS was thus used in study I primarily to be consistent with previous 
Gothenburg MCI study publications. A comprehensive NP test battery was 
used in study II, to raise the threshold for SCD and avoid including patients 
with objective cognitive impairment in the SCD group. The specific tests were 
selected because they predicted dementia in a previous study. A smaller NP 
test battery was used in study III. That paper focused on prediction of AD 
dementia, which was the rational for choosing the four test variables that 
predicted AD dementia in a previous study. (In that previous study, more test 
variables predicted AD dementia, but we only selected the best predictor 
variable from each test.) Study IV had a broader approach to dementia 
conversion (not just focusing on AD dementia), and therefore a more 
comprehensive test battery was used, using the same number of tests as in study 
II. However, it was not possible to choose identical tests as in study II, due to 
that the samples differed somewhat and we had limited resources to carry out 
follow-up visits in the SASCI-Q-cohort. Also, we prioritized choosing an equal 
number of tests from each cognitive domain. 
Some impairment in cognitive tests will be present also in normal healthy 
aging populations, due to normal variation. It may be argued that the important 
difference between healthy controls and patients in this context is therefore not 
an absolute separation when it comes to objective cognitive performance, but 
rather that patients experience a cognitive decline that affect their daily life 
enough to make them seek health care. As healthy controls are not help seeking 
patients, they were not classified using the GDS or NP test battery, but it was 
established through clinical interviews and assessment that they had no 
subjective or objective cognitive impairment.  
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4.3 Determination of cut-offs 
In study I, cut-offs for GDS were determined based on the consensus 
classification within the Gothenburg MCI study. In study II-IV, cut-offs for 
NP tests were based on results from ‘in-house’-healthy controls, enrolled in 
the Gothenburg MCI study. The control group was stratified based on age and 
years of education, to reduce the potential influence of these factors on the test 
results. Thus, when there was a significant test difference between healthy 
controls of high/low age and high/low education, patients were only compared 
to healthy controls of their own age/education group. In study II, MCI was 
defined as scoring at least 1.5 standard deviations (SD) below the means of 
controls on any of the 10 test variables. If this was not fulfilled, patients were 
classified as SCD. In study III, focusing on SCD and ‘preclinical AD’-criteria 
[7], we needed to define patients with ‘subtle cognitive decline’ which is part 
of ‘preclinical AD’ stage 3. ‘Subtle cognitive decline’ is not a well-defined 
category, but it should be placed between SCD and MCI on the cognitive 
continuum. In study III, SCD, ‘subtle cognitive decline’, and MCI were 
defined as having 0; 1; or 2/2+ test scores at least 1.5 SD below the healthy 
control mean, respectively. In study IV, not addressing ‘subtle cognitive 
decline’, we again used the same cut-off as in study II – at least one impaired 
test score defined MCI, otherwise the patients were categorized as SCD. This 
study also included categorizing single-domain MCI (defined as 1-2 impaired 
tests within only one cognitive domain) and multi-domain MCI (1-2 impaired 
tests in at least two domains). Additionally, medical records were reviewed to 
establish that all SCD patients were truly help-seekers based on their own 
account (not just prompted to seek help by e.g. their spouse).  
 
4.4 Depressive and anxious symptomatology 
Different methods were used to determine depressive/anxious 
symptomatology, primarily because of varying availability of data. The 
Hospital anxiety and depression scale, HADS [225], was used to assess 
depressive symptoms (HADS-D subscale) and anxious symptoms (HADS-A 
subscale) in study I and IV. In study II – the one study that had greater focus 
on affective symptoms – we used the clinician’s assessment at baseline visits 
as a measure, which had been registered in the fixed study protocol as ‘current 
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symptoms’ or ‘previous symptoms’, also specifying type of symptoms. In 
study III, depressive symptoms were assessed with the Montgomery-Åsberg 
depression scale, MADRS [226], or the 20-item Geriatric Depression Scale 
[227, 228]. The explanation for data from two scales is that the Gothenburg 
MCI study changed instruments a few years into the study. 
 
4.5 Psychosocial stress 
This variable was only considered in study II, and was assessed through a 
review of all medical records (blinded for other patient data, performed by 
M.E.), searching for entries describing stress-related conditions, which were 
subsequently categorized (refer to study II for details). Even though we did not 
have access to data from a validated instrument focusing on stress, we chose 
to pursue this issue based on the clinical experience that many – especially 
younger – patients at the memory clinic reported ‘stress conditions’. Stress is 
a multi-faceted term, and in the context of study II we defined it as a state of 
perceived mental or emotional strain or tension resulting from adverse or 
demanding life circumstances.  
 
4.6 Informant-reported cognitive function 
Informant-reported cognitive function was analyzed in study II as a to measure 
symptom duration, development and type from the informant’s perspective 
(data on specific features of subjective symptoms were not available for this 
sample). In study III, informant-reported cognitive function was part of the 
SCDplus criteria. We used the CIMP-QUEST, which was developed to 
identify signs related to dementia by informant-report [162] and was part of 
the Gothenburg MCI study protocol.  
 
4.7 CSF AD biomarkers and APOE 
CSF AD markers Aβ, t-tau and p-tau were included in study II-IV. The CSF 
samples were obtained by lumbar puncture, performed in the morning to avoid 
influence from possible diurnal fluctuations. CSF Aβ1-42 concentrations were 
determined using the INNOTEST® ELISA assay technology (Innogenetics, 
72 
 
Ghent, Belgium) [229]. The axonal damage marker CSF T-tau and CSF 
concentrations of tau phosphorylated at threonine 181 (P-tau181) were 
measured using INNOTEST® ELISA assays [230, 231]. In study II and IV, a 
CSF AD profile was calculated using the formula (Aβ42/p-tau > 3.694 + 0.0105 
x t-tau), suggested by Mattsson et al. [182]. In study III, we needed to analyse 
the CSF markers separately due to the ‘preclinical AD’-criteria, and therefore 
used separate cut-offs, previously used for prediction of AD (Aβ ≤482 ng/L; t-
tau ≥320 ng/L; p-tau ≥52 ng/L; [182]). 
Whole blood was collected from all participants in the Gothenburg MCI study, 
and APOE genotyping was performed by mini-sequencing as described 
elsewhere [232]. Presence of the APOE ε4 allele was included as a variable in 
study III, considering SCDplus-criteria.  
 
4.8 Determination of decline 
Determination of decline was only in question for the two follow-up studies 
(study III-IV). In study III, ‘cognitive decline’ was defined as either a decline 
in NP test scores or a conversion to dementia. Decline in NP tests was 
determined using ‘delta values’ – the change of scores from baseline to follow-
up. To calculate cut-offs for delta values, we again used data from healthy 
controls – for this purpose also matched considering follow-up time. For each 
test, delta values for the healthy controls were calculated. The mean delta value 
for the 25% (lowest quartile) of those controls who declined the most was used 
as cut-off for each test. The cut-off was set prior to any analyses. In study IV, 
‘progression’ was defined as conversion from one cognitive stage to another – 
from SCD to MCI or dementia, from MCI single-domain to MCI multi-
domain, or from MCI to dementia. We chose not to use delta values in study 
IV, primarily to simplify the description of decline. ‘Decline’ and 
‘progression’ are used as interchangeable terms in study III and IV.  
 
4.9 Dementia diagnoses 
Conversion to dementia was only in question for study III and IV. In the 
Gothenburg MCI study, all patients that were categorized as GDS 4/4+ were 
further assessed by a specially trained physician, considering specific dementia 
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diagnostics. The assessor was blinded to NP test results, CSF and imaging 
results (except assessment of white matter changes), to avoid circularity. AD 
was diagnosed according to the NINCDS-ADRDA criteria [233] – in addition 
to fulfilling general dementia criteria the patient must have no or only mild 
white matter changes, and AD-related symptoms such as associated with 
memory-, language- and visuospatial domains. Vascular dementia forms were 
diagnosed as either subcortical vascular dementia (signified primarily by 
substantial white matter changes) [234] or cortical vascular (stroke-related) 
dementia - the NINDS-AIREN criteria [235]. A MixD diagnosis in the 
Gothenburg MCI study is a combination of AD/subcortical vascular dementia 
or AD/cortical vascular dementia. Frontotemporal dementia was diagnosed 
according to Neary et al. [236]; Lewy-body dementia according to McKeith et 
al. [237]; primary progressive aphasia according to Gorno-Tempini et al. 
[238], and dementia non ultra descriptum (unspecified dementia, NUD) 
diagnosis according to the ICD-10 [3].  
Study IV partly included follow-up of patients who were not included in the 
Gothenburg MCI study. Due to limited resources, it was not possible to 
perform an identical diagnostic assessment as in the Gothenburg MCI study on 
this patient group. We instead used clinical diagnoses set in the memory clinic, 
retrieved from medical records, and based on ICD-10 criteria.  
 
4.10 Procedures 
4.10.1 Qualitative phase of study I 
The initial and qualitative phase of the project leading to the development of 
SASCI-Q was completed in collaboration with researchers from the 
department of Oncology, Sahlgrenska university hospital. They originally 
initiated the project to investigate cognitive symptoms in cancer survivors 
[239]. The symptom assessment method developed by Steineck and colleagues 
[240] involves several key standpoints: a symptom is a subjective evidence of 
disease or physical disturbance observed by the patient [29, 30] and must, per 
definition, be noticed by self-assessment. When the objective is symptom 
assessment, an assessment made by a clinician or researcher is very sensitive 
to bias, as it is an interpretation by an external evaluator. The patient ‘owns’ 
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her own symptoms. Furthermore, validity of a symptom assessment instrument 
is obtained if respondents from the target group acknowledge the accuracy of 
the questions asked, in relation to the investigated phenomenon. This validity 
is obtained through ‘face validation’ – sitting together with respondents, 
observing difficulties and discussing the wording of questions to ensure that 
they are understood correctly. It is important that items be based on actual 
patient-reported symptoms, not further interpreted by the researcher or 
constructed based on theory about the phenomenon. The proximity to the 
patients’ experience is ascertained through comprehensive interviews with 
open-ended questions, applying the groundwork for the construction of 
questions. Additionally, it is preferred that one symptom at a time is analyzed 
(‘one conceptual entity’). To summarize items into scores, as is otherwise 
common in psychometric instrument development, is considered to result in 
less distinct information about the studied phenomenon. That is, a score of ‘10’ 
compared to a score of ‘15’ on a summarized symptom scale gives very little 
information about the actual symptoms experienced. It is preferred that the 
number of occasions that the symptom has been experienced is reported 
(incidence or prevalence), instead of symptom intensity, which is considered 
more arbitrary. The time frame for symptoms (e.g. ‘in the last month’) should 
be specified in the questions. [240] 
In the qualitative phase of our study, memory clinic patients and cancer 
survivors were interviewed to generate a pool of items. Items were condensed 
through qualitative methodology and comments and input from patients were 
carefully considered in the design of the questions. Items that were specifically 
directed toward the cancer population were excluded in the memory clinic 
version, and a section on ‘cognitive change’ was added instead, due to the 
importance of ‘change’ for the current research. Refer to study I for more 
details concerning the qualitative procedure.  
 
4.10.2 Baseline procedures 
All included patients were already enrolled at the Sahlgrenska memory clinic 
at the time of study inclusion and baseline examinations. This is potentially 
important in this context due to the risk of some individuals otherwise over-
reporting symptoms in order to be scheduled for further examinations. For 
referral acceptance at the clinic, the patient had to have undergone a CT scan, 
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primarily to rule out other causes of cognitive impairment such as tumors and 
subdural hematoma. If patients fulfilled Gothenburg MCI study criteria, at 
their first visit to the clinic, they were asked to participate and written informed 
consent was collected. The Gothenburg MCI study was designed to follow 
clinical routine as closely as possible. At the first visit, blood sampling, 
cognitive function assessment scales and cognitive screening were completed. 
The cognitive screening tests are later the basis of GDS staging. In following 
visits, lumbar puncture and NP examinations were performed. NP 
examinations were conducted by licensed psychologists, and consisted of 
approximately 20 tests during 2 visits á 1.5 - 2 hours – the test battery 
somewhat changed over the years of the study. The tests used for analyses in 
the current thesis are specified in the separate reports.  Blood flow 
measurement (SPECT) and magnetic resonance imaging (MRI) were 
performed in other hospital locations – this data was not used in the current 
thesis. The patients referred to as the ‘SASCI-Q cohort’ were asked to 
participate by a registered nurse. The specific procedure of the SASCI-Q data 
collection is described in detail in study I.  
 
4.10.3 Follow-up procedures 
The aim of the Gothenburg MCI study has been to repeat examinations every 
two years, with some exceptions: NP examinations were not performed year 4. 
Patients categorized as GDS 2 year 2 were not followed up again until year 6. 
Follow-up rounds were conducted largely using the same procedures as at 
baseline. Follow-up data (NP test scores and dementia diagnoses) were 
analyzed in study III and IV. In study III, the average follow-up time was 4 
years (± 2.9 years), and in study IV 4.9 years (± 2.1 years). In both studies, 
only two points of measurement were analyzed – baseline and the last available 
follow-up. For the SASCI-Q sample, only one follow-up round was performed, 
during 2015-2016. Patients were invited to the follow-up study by mail and 
telephone. Inclusion entailed completion of the SASCI-Q questionnaire, 
approving of data being collected from medical records, and a follow-up visit 
at the clinic. At the visit, a research assistant performed NP tests and a licensed 
psychologist (M.E.) subsequently reviewed the results. Based on ethical 
considerations, it was decided beforehand that any patient who would be 
identified as cognitively impaired during the testing would be offered an in-
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house referral to the memory clinic. However, there were no such cases, as all 
patients with objective cognitive impairment already had ongoing contact with 
primary care or the memory clinic. As a service to the participating patients, 
those who inquired about test results or expressed worry about possible 
cognitive decline received feedback by a licensed psychologist (M.E.), by 
letter or telephone.  
 
4.11 Statistical analyses 
 
4.11.1 Statistical methods 
In all studies, independent samples t-test and Χ2 test were used to compare 
characteristics between groups, such as age and years of education.  
Study I and IV dealt with items from the SASCI-Q. These were analyzed item-
by-item in study I, and also dichotomized and summarized in study IV (refer 
to study IV for details). In both studies, parametric tests such as one-way 
between groups analysis of covariance (ANCOVA) were used to compare 
mean group scores for items. This was conducted despite of data being of 
ordinal rather than interval type. Refer to the next section for a discussion of 
parametric vs non-parametric methods.  
In study I, Pearson’s correlation was used to analyze the association between 
a single question about memory and all separate SASCI-Q items, as a measure 
of convergent validity. Cronbach’s alpha was used to assess internal 
consistency reliability. Before any analyses, items were categorized by co-
authors with respect to cognitive domains and considering general/specific 
question type and load on social functioning.  
Binary logistic regression analysis was used to analyze which variables 
predicted SCD (cross-sectional; study II) and cognitive decline, dementia and 
AD dementia (longitudinal; study III).  
Sensitivity, specificity and likelihood ratios were calculated to assess 
predictive ability of SCD criteria and ‘preclinical AD’ criteria (study III), in 
relation to cognitive decline, dementia and AD dementia.  
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In study IV, Pearson’s correlation and partial correlation were used to analyze 
the relationships between subjective cognitive symptoms on the one hand, and 
CSF AD biomarkers and depressive/anxiety symptoms on the other hand. T-
test and ANCOVA were used to analyze group differences between separate 
SASCI-Q items.  
Covariates such as age were generally taken into account only if differences 
between groups were statistically significant. The alpha level for significance 
was p<.05, however Bonferroni corrected results were presented in study I and 
IV due to the high number of variables. SPSS was used for all statistical 
analyses.  
 
4.11.2 Statistical issues 
There has been controversy for decades about the practice of using parametric or non-
parametric tests with ordinal and non-normally distributed data. For scientific 
measures, unusually harsh standpoints have sometimes been used when discussing this 
issue, including stern comments like “using parametric analysis for ordinal data is the 
first of the seven deadly sins of statistical analysis” [241], and on the other side that 
reviewers’ seemingly automatized demand for non-parametric methods is 
“overvaluation of criticism for its own sake, inappropriate statistical dogmatism’’ 
[242]. To address this controversy, Norman [243] conducted a review of the 
assumptions of various statistical methods and the potential problems when the 
assumptions are violated. He argues that it is a misconception that data needs to be 
normally distributed to use parametric tests. It is the means – not the data – that should 
be normally distributed. According to the central limit theorem, means are 
approximately normally distributed regardless of the original distribution, for sample 
sizes greater than 5 or 10 per group. This theorem has also been supported by empirical 
studies, showing that parametric tests such as ANOVA and Pearson’s correlation, are 
highly robust to e.g. skewness and non-normality [243]. Norman concludes:  
“Parametric statistics can be used with Likert data, with small sample sizes, with 
unequal variances, and with non-normal distributions, with no fear of “coming to the 
wrong conclusion”. These findings are consistent with empirical literature dating back 
nearly 80 years. The controversy can cease (but likely won’t).” [243] 
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4.12 Approvals from the ethics committee 
The Gothenburg MCI study was approved by the local ethics committee (diary 
number: L091-99 15 March 1999/T479-11 8 June 2011). Written informed 
consent was obtained from all participants in the Gothenburg MCI study (study 
II-III, and sub-samples in study I and IV) and in the follow-up study visits of 
the SASCI-Q cohort (study IV). For the SASCI-Q data-collection (study I), a 
separate ethics approval was sought and received (2009, diary number: 649-
08), in which the ethics committee deemed verbal informed consent as 
sufficient. An amendment to this approval was later sought and permission was 
received to carry through the follow-up visits presented in study IV.  
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5 SUMMARIZED RESULTS 
 
5.1 Study I 
Study I presents the development and initial validation of a self-assessment 
instrument to measure SCD – the SASCI-Q.   
The main objective of the study was to develop a patient-based comprehensive 
instrument on everyday cognition, identifying questions which separated 
between SCD patients and healthy controls – in other words, designing an 
instrument based on cognitive symptoms more often reported by help seekers 
without detectable cognitive impairment, compared to healthy older adults. 
Another objective was to investigate the cognitive spectrum of subjective 
cognitive symptoms in memory clinic patients with SCD – were all cognitive 
domains represented or not? 
The 97 original items that were generated mainly from patient and informant 
interviews were reduced to 45 items that separated significantly between 
healthy controls and SCD patients. The psychometric properties – here 
referring to convergent validity (level of correlation with a measurement based 
on the same theoretical construct) and internal consistency (level of correlation 
between items) - were assessed as satisfying. Considering the spectrum of 
cognitive domains, it was found that the majority (62%) of items separating 
between healthy controls and SCD patients were related to the memory 
domain, although the domains of speed, attention, executive functions and 
language functions were also represented. No items related to the visuospatial 
domain separated between groups and were therefore not included in the final 
version of the instrument.  
 
5.2 Study II 
The main objective of study II was to investigate the prevalence of 
considerable psychosocial stress, depressive symptoms and CSF AD profile in 
memory clinic patients with SCD vs MCI. In line with our hypothesis, we 
found that SCD patients were generally characterized by high levels of stress 
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– over 50% of the sample, but low occurrence of CSF AD biomarkers – 14%. 
The prevalence of current depressive symptoms was largely similar in SCD 
and MCI groups. Reporting previous depressive symptoms was however 
significantly more frequent in SCD compared to MCI. Simultaneous reports of 
both stress and depressive symptoms – implying a greater load of affective 
symptoms – were more than two times more frequent in SCD compared to 
MCI. High levels of stress, more years of education and a negative CSF AD 
profile predicted SCD. The odds for belonging to the SCD group rather than 
the MCI group were 2.5 times higher for patients who reported previous or 
current stress. In addition to the main findings, we observed that the prevalence 
of SCD in the total non-demented patient sample was 36%, and that SCD 
patients on average were younger and had more years of education compared 
to MCI patients. 
 
5.3 Study III 
The objective of study III was to examine several variants of different SCD 
criteria and ‘preclinical AD’ criteria, concerning the proportion of progressing 
patients, and predictive ability of the criteria – both as clustered criteria and 
with respect to individual criteria. In other words, which variables predict 
progression in patients with SCD? 
We observed that 39% of the 122 SCD patients had declined cognitively 
between baseline and follow-up, compared to 61% in the MCI/’subtle 
cognitive decline’-group. As expected, only a few (10%) of the SCD patients 
had developed dementia (although more than what would be expected in the 
healthy aging population during the same amount of time) – the majority of 
cognitively declining patients declined only in neuropsychological scores 
(=converted to MCI) during the follow-up time. By adding biomarker criteria 
to the SCD-group, the proportion of declining patients significantly increased 
– especially the criteria for ‘preclinical AD stage 2’ (both Aβ and tau markers 
positive) was observed as a successful predictor of progression. In patients 
categorized as ‘preclinical AD stage 2’, 81% converted to MCI or dementia, 
as compared to 39% in the total SCD group. When analyzing criteria 
separately, CSF Aβ was the only significant predictor of progression.  
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5.4 Study IV 
The main objective of the study was to investigate differences in baseline 
subjective cognitive symptoms, using SASCI-Q, between progressing and 
non-progressing patients. Secondly, to investigate if any differences could be 
observed between SCD and MCI patients, with respect to baseline subjective 
cognitive symptoms in MCI and SCD patients, in relation to cognitive outcome 
and CSF AD biomarkers. We reasoned that it could indicate poor awareness if 
patients with verified cognitive impairment reported low levels of subjective 
symptoms. 
Somewhat counterintuitively, when analyzing the entire sample consisting of 
both SCD and MCI patients, progressing patients did not report more cognitive 
symptoms at baseline for any of the 45 SASCI-Q items, compared to patients 
who did not progress. However, these results changed – and were somewhat 
explained - when the groups were separated into SCD and MCI: progressing 
SCD patients reported significantly more cognitive symptoms at baseline 
compared to their non-progressing counterparts, whilst progressing MCI 
patients reported significantly less cognitive symptoms compared to their non-
progressing counterparts. With respect to specific items, progressing SCD 
patients reported significantly more symptoms for five items, compared to non-
progressing SCD patients: ‘someone else said that you did something you can’t 
remember doing’; ‘difficulties learning phone numbers by heart’; ‘had the 
feeling that you planned to do something, without remembering what it was’; 
‘someone else reminded you about something’; and ‘difficulties findings 
words compared to when you were 25 years old’. However, for most items, 
there was no significant difference between progressing and non-progressing 
patients. Interestingly, in SCD patients, reporting more cognitive symptoms 
correlated with having pathological concentrations of CSF AD biomarkers. 
Again, the results were reversed in MCI patients – reporting less cognitive 
symptoms correlated with having pathological concentrations of CSF AD 
biomarkers. The associations between depressive/anxiety symptoms and 
subjective cognitive symptoms were generally strong, especially in non-
progressing patients.  
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6 DISCUSSION 
 
The objective of this thesis was to investigate SCD in memory clinic patients 
with respect to characteristics and clinical relevance. ‘Characteristics’ firstly 
refers to features that may characterize patients with SCD, and secondly to the 
specific type of symptoms reported by patients with SCD. ‘Clinical relevance’ 
refers to the degree of association between SCD and cognitive decline and 
dementia. 
 
6.1 Characteristics of patients with SCD 
Per definition, SCD patients scored higher on neuropsychological tests (study 
II-IV) and cognitive screening tests (study I). When compared with MCI 
patients, the patients with SCD in our studies were of younger age and had 
higher education (study II-IV); which is in line with other clinically based 
studies [192, 244] but contradicts population-based findings, showing an 
association between SCD and higher age/lower education [36]. As has 
previously been mentioned, it is important to acknowledge the differences 
between findings generated in different research settings.   
Compared to MCI patients, SCD patients reported more psychosocial stress 
and more previous depressive symptoms (study II). Specific subjective 
cognitive symptoms were more strongly associated with anxiety/depressive 
symptoms than with subsequent cognitive decline (study IV). These findings 
correspond to previous reports, showing firm evidence of an association 
between affective factors and cognitive symptoms [83-87]. Additionally, not 
only current but also previous affective states may help explain SCD. Taken 
together, the complex interrelationship between cognitive and affective 
symptoms clearly complicates the application of SCD as a marker for objective 
cognitive decline, which is further discussed below.   
As compared to MCI patients, SCD patients were less likely to display 
pathological concentrations of CSF AD biomarkers (study III; however the 
difference was not significant in study IV when analysing a smaller sample); 
less memory difficulties as reported by an informant (study III); and scored 
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slightly higher on the MMSE (study IV, however non-significant difference in 
study III). These findings were expected because MCI per definition entails 
more cognitive impairment. However, not all studies have been able to 
establish a CSF AD biomarker difference between SCD and MCI, especially 
not in smaller samples [1]. Features that did not differ significantly between 
SCD and MCI patients were current depressive symptoms or anxiety, and male 
vs female sex. As was further discussed in study II, depressive symptoms thus 
seem less specific to the SCD group, compared to stress conditions.  
The differences between SCD patients and healthy controls were only analysed 
in study I, showing that there was an equal level of education years; that SCD 
patients were younger than controls; reported more depressive symptoms; and 
had slightly lower mean scores on MMSE (although the mean difference was 
only 0.3 points). The most important difference between SCD patients and 
healthy controls was the main result of study I – for all the 45 final items in the 
SASCI-Q questionnaire, SCD patients reported more frequent symptoms 
compared to healthy controls. This result suggests that it is possible to identify 
cognitive symptoms that are more frequently reported by individuals who seek 
help for their cognitive problems compared to ‘general cognitive complaints’ 
in healthy older adults, which is an important aspect of separating potentially 
clinically relevant symptoms.  
Unpublished results showed that having a family history of dementia (affected 
parents or siblings) was more than twice as frequent in SCD (65%) as in 
healthy controls (29%). Furthermore, there were no significant differences 
regarding presence of APOE ε4 between SCD and MCI or between SCD and 
healthy controls. In my opinion, especially patients who report having a family 
history of dementia should be thoroughly interviewed before being enrolled as 
patients. To what degree have they actually experienced cognitive symptoms, 
and to what degree have they sought help ‘just in case’, or to ease worries about 
heredity. In my experience, many patients have misconceptions about e.g. 
genetic risk factors. Some are convinced that they will develop dementia if 
both parents had dementia, which certainly does not have to be the case. These 
individuals would gain from receiving more facts about prevalence, different 
dementia disorders, heredity and risk.  
In total, the factors that we observed as typical characteristics of SCD patients 
correspond well with the health belief model (HBM, section 2.7.7) describing 
86 
 
factors associated with higher vs lower likelihood of medical help seeking. 
According to the HBM, perceptions about what should be regarded as ‘normal’ 
or not, are factors associated with the likelihood of help seeking. In the current 
studies, younger age was a characteristic of the SCD patient group. Plausibly, 
when cognitive symptoms are experienced before retirement age, individuals 
may be more likely to consider them as troubling and unexpected compared to 
their peers. Older individuals may be less likely to seek help for subtle 
cognitive difficulties if they perceive them as part of normal aging – which 
may be partly accurate given what is known about cognitive aging processes, 
but also may be affected by negative stereotypes about aging.  
Knowledge about symptoms is another factor associated with help seeking in 
the HBM. On average, SCD patients may have a wider knowledge/interest of 
dementia symptoms than general, e.g. reflected by their higher education level 
and the frequent occurrence of a family history of dementia. ‘Cues to action’, 
such as whether an individual is prone to seek medical care or not (for any 
symptom), is another factor in the HBM. A higher frequency of medical help 
seeking has been observed in individuals with higher educational attainment 
[245], which may partly explain our findings. Having a family history of 
dementia may also be related to the factor ‘perceived susceptibility’ in the 
HBM – individuals worrying for ‘inheriting dementia’ may be more likely to 
perceive themselves as more susceptible to disease.  
Younger age may also indicate that individuals are more likely to still be 
employed, and thereby meet more cognitive challenges in daily life – not least 
associated with the increasing demands of technical skills in the workplace. 
However, it cannot be excluded that the younger mean age of SCD patients 
compared to MCI patients is simply a result of dementia being associated with 
age.  
6.2 Characteristics of specific symptoms 
The other aspect of characteristics of SCD refers to which type of symptoms 
that are reported. In study I, we started out with a questionnaire based on 
interviews with patients. Thus, it was not predetermined that a certain number 
of items should be included for each cognitive domain. By analysing data as 
presented in study I, the number of items were further reduced to only include 
those showing a significant difference between SCD patients and healthy 
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controls. The final items were unevenly distributed across the cognitive 
domains. Most items showing a difference between SCD patients and healthy 
controls were clearly associated with the memory domain – with sporadic 
items that were considered as more associated with other cognitive domains 
(attention/speed-, executive-, language- or mixed domains). Obviously, this 
was not surprising given that the sample consisted of patients at a memory 
clinic. Several of the memory items phrased as “did someone else remind 
you/say to you…[e.g. that you have a poor memory]”. Possibly, these 
questions have an increased clinical relevance in that they indicate that others 
noticed the cognitive problems. On the other hand, a previous study found that 
being assessed as more forgetful by others was more common in younger 
respondents [38]. Other memory items were mostly related to problems noticed 
in everyday situations, such as when talking to others, remembering what you 
or others have said, remembering facts and learning new things. No questions 
in the final version were associated with the visuospatial domain. Similar 
findings were reported by two previous studies [64, 65] (although contradicted 
by another study in which difficulties with finding one’s way around familiar 
streets was associated with objective cognitive impairment). This finding was 
somewhat unexpected, as problems with spatial orientation are known as 
dementia related symptoms. However, other cognitive domains such as 
memory and language (AD dementia), or executive functions and attention 
(vascular forms) are typically affected prior to the visuospatial domain. 
Another possible explanation is that complex visuospatial tasks may be easier 
to avoid in daily life for those with poor visuospatial ability than, for example, 
verbal tasks. 
The developed instrument SASCI-Q has similarities – especially considering 
the broad spectrum of cognitive domains –  with a couple of other 
questionnaires developed during the same time period, such as CDQ [69], 
SCD-Q [72], and the items suggested by Gifford et al. [75], but there are also 
important differences. The CDQ was also developed in Swedish, but was based 
on a sample from the general population. It was in part developed through 
statistical analysis that clustered items into components. Items were validated 
based on their correlation to cognitive tests – with the rationale that items that 
maximize the coherence between self-assessment items and objective 
performance should be maximized – and on the negative correlation to 
depressive symptoms. Thus, the CDQ and the SASCI-Q are likely valid for 
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different populations and different research questions, given the differences in 
construction methods, target population, and the underlying view on symptom 
validity. Considering SCD-Q [72], the most important difference compared to 
the SASCI-Q considers the construction of items – an expert panel generated 
items for the SCD-Q whilst we used patient interviews in our construction 
phase of SASCI-Q. Other differences are that the SCD-Q includes one self-
report section and one informant-report section, whilst the SASCI only 
includes self-assessment, and the questions in the SCD-Q are dichotomous 
yes/no questions, whilst questions in the SASCI-Q are formulated in terms of 
prevalence and incidence, to offer a more detailed report. On item-level, the 
SASCI-Q and the SCD-Q share several items, such as ‘difficulties learning 
new phone numbers’, ‘finding personal possessions’, and ‘finding words in a 
conversation’.  
 
6.3 Clinical relevance of SCD 
Assessing pre-dementia stages is a puzzle. All currently available methods for 
assessing early signs of sporadic forms of dementia, even those elevated to 
‘biomarkers’, have well-known limitations of sensitivity and specificity. As of 
yet, no markers perform well enough to be considered surrogates of disease. 
The complex nature of SCD that the current studies and many other have 
recounted, obviously limits the usefulness of the SCD concept as a marker for 
disease. Despite using a carefully developed self-report instrument, we 
observed only a weak association between specific subjective cognitive 
symptoms and subsequent cognitive decline. However, we did identify five 
items for which progressing SCD patients reported more frequent symptoms 
compared to non-progressing SCD patients, in contrary to entirely negative 
findings reported previously (although that study included a mixed sample of 
SCD and MCI patients) [215]. These items, and others showing some, but non-
significant differences, may be interesting to explore further longitudinally in 
larger samples. Especially as very few studies so far have investigated the 
predictive value of specific symptoms — or perhaps, negative findings were 
not reported.  
Relatively few individuals with SCD (10%) converted to dementia over time 
(mean 4 years). This number however corresponds well with the findings of a 
large meta-analysis, reporting a 5-year conversion rate from SCD to dementia 
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of 11% [79] – twice as many converters compared to individuals without SCD.  
Thus, as could be expected, within the heterogeneous SCD group certainly 
some individuals will develop dementia. It cannot be excluded that the results 
would have been different with longer follow up time and larger samples. 
However, the associations between SCD and affective factors were 
considerably more convincing compared to the associations between SCD and 
any objective sign of underlying neurodegenerative disease. That said, in my 
opinion SCD cannot compete in clinical relevance with e.g. the MCI concept, 
neuropsychological tests, brain imaging or neurochemical analysis. There is 
not enough evidence to support SCD as a ‘fourth pillar’ of pre-dementia 
assessment, or as of equal predictive value compared to MCI. SCD cannot 
stand on its own as a clinically relevant concept in relation to disease progress 
– it is far too lacking in specificity. However, the association between SCD 
and subsequent dementia becomes apparently more relevant if there are 
simultaneous positive objective markers for ongoing neuropathological events. 
We observed that 81% of SCD patients with both positive amyloid and tau 
markers (=‘preclinical AD stage 2’) converted to MCI or dementia over a mean 
of four years, as compared to 39% in the total SCD group. Other markers – such 
as imaging markers – may be equally valuable, although not investigated in 
this thesis. However, the entire population cannot be screened by lumbar 
puncture. Even if markers in blood were improved, it would be highly unethical 
to screen the population when treatment possibilities for dementia are still 
lacking. That is what makes SCD important despite its ‘fuzziness’ - there is 
currently no other way to identify individuals who may benefit from dementia 
screening, than by symptom report. That is how patients communicate their 
difficulties. Thus, striving to validate subjective cognitive symptoms as 
markers for future dementia is likely to overstate its potential diagnostic value. 
However, there are several other areas in which self-report of cognitive 
symptoms may be useful. Studies comparing help-seekers with individuals 
who choose not to seek help despite experiencing cognitive symptoms are 
potentially important, because they increase knowledge about which persons 
choose to seek help. Such studies should also investigate how cognitive 
symptoms may be perceived, described, and associated to help seeking 
differently in different demographic groups, in both clinical and population 
based samples. It is well known that neuropsychological assessment of persons 
with a different native language is a challenge. Although it needs to be 
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investigated, self-report of cognitive symptoms may be a more important 
complement to neuropsychological tests in groups that are difficult to assess 
using standardized neuropsychological tests and norms based on native 
Swedish speakers.  
In patients with stress conditions, cognitive problems may be difficult to verify, 
due to that their problems may be mostly noted in real-life situations with 
overwhelming stimuli. In these patients, self-assessment of cognitive 
symptoms could perhaps be – and is likely already – used as a basis for 
interventions and therapy. 
The role of subjective cognitive symptoms in MCI has been debated. In the 
original criteria, ‘memory or other cognitive complaint’ was part of the criteria 
[246], although later criteria include that subjective symptoms should be 
corroborated by an informant [24]. Some have argued that subjective 
symptoms should be excluded from the MCI criteria altogether, due to its 
complex nature and contradictory findings [68, 76]. Researchers focusing on 
subjective symptoms have also highlighted that studies should separate 
between SCD and MCI, to enable separate evaluations of the two concepts as 
different stages on the dementia continuum [46]. We observed a curvilinear 
relationship in study IV – an association between more subjectively reported 
cognitive symptoms at baseline and future objective cognitive decline in 
patients with SCD, but the opposite in patients with MCI. A similar 
relationship has been observed by a previous study [68]. These results indicate 
that the clinical value of SCD is higher before objective cognitive signs are 
detectable. As has been previously acknowledged [68], SCD may thus be more 
confusing than clarifying in patients with MCI, because of the reduced 
symptom awareness that seem to affect some people even before a manifest 
dementia state. Results from study IV indicated that, before objective cognitive 
signs are observable, having subjective cognitive symptoms seems to be a 
more reliable indicator of subsequent decline. However, the level of ability 
awareness or ‘meta-cognition’ can be compromised also in the general 
population. Self-assessment may be affected by many factors, and is not an 
objective report of the cognitive state, as it would be described when measured 
by tests, which should always be kept in mind. 
The differences in SCD based on different research settings have been a 
recurring point in this thesis. Although the differences between SCD in the 
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population and clinical settings were not investigated in the current studies, 
findings from previous studies have shown that the conversion rate in SCD is 
higher in clinical than in population-based samples [78]. Consequently, the 
clinical relevance of the SCD concept is higher in clinical settings. If 
screenings using biomarkers are to be conducted, e.g. for medical treatment 
interventions, a clinical SCD sample is likely more suitable as a target group 
compared to a community-based SCD sample.  
To summarize the theme of clinical relevance, the results from this thesis 
indicate that there is some clinical relevance of SCD (as a patient category as 
well as specific subjective cognitive symptoms) as a predictor of future 
cognitive decline, but it should not be overstated. However, when CSF 
biomarkers indicate possible pathology, there is evidence to suggest that 
patients with SCD should be further investigated.  
 
6.4 Functional memory disorder (FMD) – a 
justified concept 
It has been suggested that another term is needed to distinguish persons with 
cognitive symptoms that are more likely to be related to dementia, from 
persons with cognitive symptoms that are potentially reversible and thought to 
be caused by emotional or psychological factors – that is, not caused by a 
neurological condition [247, 248]. A proposed term is FMD – functional 
memory disorder. It was first presented with criteria in 2008 [249] but has 
received much less attention than SCD – there are only nine publications on 
PubMed concerning FMD (April 2017). Since SCD is primarily a concept 
concerning the dementia realm, there is certainly a need of a parallel concept 
describing another etiology and trajectory. Especially as a majority of 
individuals with SCD will likely not develop dementia.  
FMD has often been used for younger populations, and age >70 years is 
considered exclusion criteria in the original FMD criteria. However, the 
concept may just as well be applied in the aging population. FMD has been 
associated with above-average education and socio-economic attainment [250, 
251], and is related to depressive symptoms, a ruminative style of thinking, a 
perfectionist attitude toward memory, and experiencing stress-related events 
92 
 
such as interpersonal conflicts, overwork, and distressing life changing events 
[249]. Besides the age criteria, the criteria of SCD and FMD differs in that 
FMD includes presence of ‘psychosocial burden’ and absence of a 
recognizable organic cause of cognitive impairment. The similarity between 
FMD and the characteristic profile we observed in many of our SCD patients 
is thus apparent – high educational attainment, stress, and depressive 
symptoms.  
Schmidtke suggested that these factors may spiral into a ‘vicious cycle’ of 
worry and cognitive failures [249]. A few studies have analysed the effects of 
short-time counselling with help seeking individuals categorized as FMD, 
focusing on e.g. reassuring that test results were normal, and educating people 
about stress-induced cognitive impairment [252, 253]. The studies could 
generally not establish sufficient evidence for such interventions, as the 
symptoms remained in most individuals at follow-up. Often, these individuals 
are referred via primary care again, after a few years, with the same non-
verifiable symptoms. These findings suggest that FMD, or ‘non-progressive 
SCD’, may be more difficult to treat than what could perhaps be expected. 
However, it is important to develop effective counselling and therapeutic 
strategies, as the symptoms of these individuals are potentially reversible. 
Using the FMD concept would distance the symptoms from being about ‘just’ 
dementia prediction, which seems reasonable given the non-progressive nature 
of most patients categorized as SCD.  In my opinion, FMD is therefore a 
potentially useful concept to use in memory clinics. 
 
6.5 Implications for health care services 
The current studies, as well as previous research, have shown that a large 
proportion of help seekers at memory clinics only have subjective cognitive 
decline, and the vast majority of them do not seem to progress to MCI or 
dementia. In my opinion, this finding is partly related to the organization of 
health care services.   
About half of the patients with SCD in our study II reported current or previous 
prolonged severe stress, often work related. Plausibly, a non-negligible number 
of individuals seek consultation at memory clinics even though they are rather 
convinced that their cognitive difficulties stem from stressful life 
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circumstances rather than an underlying neurodegenerative disease. These 
patients should be able to receive healthcare elsewhere, from caregivers 
dedicated to stress-related cognitive impairment. Such medical facilities exist, 
but apparently not enough to meet the needs.  The general aim of memory 
clinics is to investigate possible early signs of dementia, and to offer medical 
support and treatment for those who are likely to have a progressing disorder. 
Those who experience cognitive decline in relation to e.g. stress, depression or 
anxiety, are not the target group and there is often a lack of specialist clinics to 
refer them to. If symptoms cannot be verified by investigations, they are sent 
home – probably less worried about dementia, but likely still with cognitive 
symptoms. In my opinion, an improved availability of interventions regarding 
the cognitive impairment associated with e.g. stress disorders would be 
valuable for affected individuals as well as to make health care more efficient. 
Using the concept FMD is a potential way forward to categorizing these 
individuals more accurately. 
Overall, there seems to be a need for improved information to help-seeking 
patients – and to society – about a number of factors that are frequently 
misinterpreted: what cognitive functioning is; how it may be affected by 
different conditions and life circumstances; what can be expected in ‘normal 
aging’; and the hereditary and risk factors for dementia. For example, 
comprehensive information to adult children of patients with dementia could 
increase knowledge in the next generation. 
The cognitive implications related to conditions other than dementia have been 
curiously under-explored, but are fortunately now receiving more research 
attention, e.g. in the areas of stress conditions, intensive care, cancer, and brain 
trauma. Hopefully, health care services will follow, so that individuals with 
cognitive symptoms – regardless of etiology – will receive appropriate 
investigation, information and treatment. ‘Cognitive medicine’ may be further 
developed as a useful concept for both research and health care, to describe the 
inter-relationship between various medical conditions and cognitive 
dysfunction. 
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6.6 Strengths and limitations 
 
6.6.1 Strengths 
The phenomena in focus, subjective cognitive symptoms, were thoroughly 
investigated by developing and using a comprehensive instrument. The 
construction of questions was largely based on actual patient-report. The 
questionnaire addressed difficulties related to several cognitive domains, not 
just memory. Questions were evaluated and further developed in discussions 
with patients. The integration of qualitative and quantitative methods is a 
benefit in that they may balance each other’s strengths and weaknesses.  
The follow-up time was relatively long compared to in other similar clinical 
studies. Patients were well-characterized and investigated with multiple 
measures. Overall, it is a strength that the current thesis applies a 
comprehensive perspective on SCD – considering potential confounders as 
well as the specific symptom expression and pathophysiological correlates.  
Furthermore, the researchers and other professionals involved in conducting 
the current research were clinically experienced, and the studies reflect actual 
phenomena encountered in a memory clinic. 
 
6.6.2 Limitations 
The patients in the current studies were all active help seekers at a memory 
clinic. As has previously been discussed, SCD may denote very different things 
in a clinical setting compared to in a community-based setting. The findings 
should therefore not be generalized to experiences of cognitive symptoms in 
the general population.  Furthermore, as participation in the current studies 
partly involved responding to a comprehensive questionnaire in Swedish, the 
sample did not reflect the ethnic diversity in society. It cannot be excluded that 
individuals with different cultural origins describe symptoms differently. 
Furthermore, the degree of help seeking is known to be affected by 
demographic factors.  
Varying methods to distinguish SCD from MCI were used in the current 
studies. This may affect the possibility to compare results across studies. 
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However, the different classifications were occasionally cross-tested, showing 
similar results regardless of classification variations.  
As in most single center clinical studies, the samples of the current studies were 
fairly small. It cannot be excluded that negative findings was partly caused by 
small sample size. Furthermore, there was a varying follow-up interval 
between patients, some being followed for 12 months and others for over 10 
years. This may partly be explained by the type of research setting – patients 
were consecutively included during 14 years. Additionally, some patients did 
not continue follow-up because of e.g. dementia, severe somatic disease or 
death.  
The possible biases involved with using healthy volunteers as controls should 
be acknowledged. It is well established that volunteers on average are more 
well-functioning than the general aging population. There is also a risk that a 
few volunteers are interested to participate because they are in fact worried 
about their cognitive functioning – it is likely less of a stigma to enrol as a 
‘healthy control’ than to become a patient. Such issues have however been 
addressed in the healthy control interviews before inclusion. Furthermore, 
when responding to a symptom questionnaire, there is a risk that healthy 
controls under-report symptoms, because they know that ‘their role’ is to ‘be 
healthy’. However, when analysing data we did not observe such pattern of 
null-responses.  
 
6.7 Ethical issues 
The increased focus in research and health care in very early phases of possible 
dementia may be a key to more knowledge about the origins of disease. 
However, there are ethical issues involved that should be accounted for. 
Firstly, it may be an ethical problem to endorse a patient’s subjective 
complaints using a diagnostic label, when there are in fact no objective signs 
of decreased functioning. Are we then ‘diagnosing’ patients when categorizing 
them as having SCD? In many scientific reports, the term ‘diagnosis of SCD’ 
is used. If ‘diagnosis’ is defined as ‘an analysis or description of the nature of 
a condition/situation’, SCD may be considered to be a diagnosis. On the other 
hand, if ‘diagnosis’ is defined as ‘identification of a disease from its signs and 
symptoms’, SCD should not be considered as a diagnosis but rather a 
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categorization or possibly a risk factor. The essential ethical issue of the 
terminology is that patients may perceive SCD, MCI or preclinical AD as 
diagnostic labels or even as pre-dementia-states, leading to the belief that they 
will inevitably develop dementia. To phrase a risk factor or biomarker to sound 
like a disease is a ‘red flag’ for possible over-diagnosis [254]. The use of the 
term ‘preclinical AD’ is therefore problematic, as it is easily misinterpreted as 
dementia being inevitably underway. SCD may be a less controversial concept, 
as it is clearly addressing the subjectivity of the symptoms, but there is still a 
risk of misuse. As Canevelli [255] stated: ”it should not be underestimated how 
many times other research conditions have almost automatically acquired 
clinical value“, pointing to MCI as an example of a ‘condition’ acquiring status 
as a diagnostic entity even though many individuals with MCI never develop 
dementia.  
On the other hand, labels and diagnoses may be helpful for validation of the 
experienced problems, confirming that clinicians take patients’ concerns 
seriously. When a previously poorly defined concept is upgraded to a 
diagnostic category, it also enables a sharper definition and operationalization, 
which increases the possibility of equal treatment across clinics and countries. 
Thus, validating a patient’s problems by naming them may not be wrong, but 
it is important that clinicians make an effort to thoroughly describe the 
meaning, uncertainty and limitations of the used classification concepts.  
A second ethical issue is that research on SCD and similar concepts require 
longitudinal follow-up over many years of patients without objective signs of 
disease. This may prevent help seeking and worried patients from moving on 
psychologically, remaining in the phase of “watchful waiting” far longer than 
what is medically justified. On the other hand, there are also patients who feel 
less worried if they receive regular check-ups. Reasonably, the psychological 
consequences for each individual study participant should be taken into 
account, by not pushing for study continuation for patients who seem to be 
negatively affected by study participation. This may partly explain why group 
sizes are generally small in memory clinic studies on SCD – the value of 
research must be weighed against the effect participation has on individual 
patients.  
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7 CONCLUSION 
The results of this thesis show that it is possible to identify specific SCD 
symptoms that are more frequently reported by patients seeking help for 
cognitive problems, compared to healthy elderly – even in patients for whom 
no objective cognitive impairment could be verified. The self-report 
instrument SASCI-Q is a useful research tool to investigate cognitive 
symptoms further.  
SCD patients are characterized by relatively young age, high educational 
attainment, high prevalence of stress conditions and depressive symptoms, and 
a family history of dementia. Even if subjective cognitive decline can have 
many causes, the SCD term is primarily used to signify a possible pre-MCI and 
pre-dementia stage. Another term, such as FMD, may be useful to describe 
individuals who have SCD with plausible affective/emotional causes.  
Only a small proportion of help seeking patients with SCD convert to dementia 
over four years, and a majority does not decline to MCI. However, when CSF 
biomarkers are added, the ability to predict MCI, dementia, and AD dementia 
increases. SCD in combination with other markers is more clinically relevant 
in relation to subsequent cognitive decline.  
The recently recommended criteria of SCD/SCDplus is an important 
development to improve research quality in this area and will hopefully lead to 
more stringent and comparable reports. However, this thesis could not 
establish most SCDplus criteria as predictors of cognitive decline. It is 
important that SCD is not misinterpreted as a diagnosis – it should only be 
conceived as a concept to categorize the presence of cognitive symptoms. 
It could not be established that specific subjective cognitive symptoms are 
associated with cognitive progression in a memory clinic sample including 
both SCD and MCI patients. However, the clinical relevance of subjective 
cognitive symptoms differed between patients with SCD and MCI, as they may 
convey a risk of deterioration at the SCD stage, but in MCI, symptom 
awareness may be reduced, and the relationship is thus reversed – less reported 
symptoms may indicate a higher risk of future decline.   
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8 FUTURE PERSPECTIVES  
The recommended criteria for SCD and the enriched SCD plus category are 
still in need of much further evaluation, in community-based samples as well 
as clinical populations. The ability to predict dementia by SCD and related 
concepts may only be truly evaluated by following patients, compared to non-
SCD controls, for 10-15 years.  
The area of specific symptoms, as opposed to summarized scales, should be 
further investigated as studies are still scarce. When the objective is to predict 
cognitive decline, is it relevant to ask multiple questions about specific 
symptoms? Or is one general question enough? 
There are possible ethical issues involved with following individuals, as 
patients, for many years without objective signs of any disease. These issues 
should be further acknowledged and investigated. Is a continuous contact with 
health care and related research calming for affected individuals, or does it lead 
to even more worry? 
Traditional neuropsychological tests are the ‘gold standard’ of assessing 
cognitive function. Many of the large tests used worldwide were developed 
decades ago, and are ‘paper-and-pen tests’ performed in a strict clinical 
environment. There are many strengths associated with these features - 
neuropsychological tests are generally convincing in terms of validity and 
reliability. However, we observed a relatively large number of individuals with 
self-reported stress conditions who had subjective cognitive difficulties, but 
for whom we could not verify cognitive impairment even by a comprehensive 
neuropsychological examination. Investigating cognition related to stress 
conditions is thus a challenge for neuropsychological method development. It 
is likely time to take even more steps toward computerization of tests. For 
example, by virtual reality (VR) technology it is possible to create precise and 
controlled dynamic multi-sensory 3D stimulus environments, as well as 
recording behavioral responses using advanced technical methods. 
Collaborations involving neuropsychology and VR technology is an exciting 
field for the future and has begun to show promising findings, e.g. in the area 
of stress-related cognitive functioning [256].  
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The aspects of help seeking is an important area to investigate further. 
Research suggests that factors such as perception of symptom severity, 
confidence in health care, a family history of dementia, knowledge about 
symptoms, and perceived risk to develop disease are some of the factors that 
affect if individuals seek help for their cognitive symptoms or not. Are there 
other factors involved that are not yet recognized? How does cultural 
background affect patterns of help seeking and symptom reporting? Is there a 
risk that different patterns of help seeking and inequality of health care 
accessibility lead to that specialized clinics over-include individuals from 
‘high-income’ areas with benign subjective symptoms, and under-include 
individuals with more severe, objective, symptoms from ‘low-income’ areas? 
Would increased efforts of education and information about e.g. cognitive 
function, stress effects on the brain, dementia, genetic risk and normal aging, 
decrease help seeking for benign subjective cognitive changes? Would a 
development of more cognitively oriented health care instances relieve the 
burden on memory clinics of help seekers with a non-neurodegenerative cause 
of cognitive symptoms?  
There is still no ‘cure’ for dementia. A breakthrough in treatment trials does 
currently not appear to be close, as several trials have failed in recent years. 
However, in the case of an effective treatment for e.g. AD, new health care 
strategies will have to be developed to meet a likely escalating number of help 
seekers. In what way these demands are going to change can only be subject 
to speculation, but if or when a medical breakthrough comes, the conditions 
for both health care services and research will likely change tremendously.  
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9 TAKE HOME MESSAGES 
 
 
 
Figure 7. Take home messages 
The recent criteria of SCD/SCDplus is an important 
development to improve research quality. However, 
this thesis could not establish most SCDplus criteria 
as predictors of cognitive decline. It is important not 
to regard SCD as a diagnosis.  
There is a need to further develop a concept, e.g. 
FMD, to describe SCD with plausible affective 
causes. 
The SASCI-Q may be used 
to identify cognitive 
symptoms that are more 
frequent in memory clinic 
help seekers without 
detectable cognitive 
impairment, than in healthy 
volunteers.  
There is a strong 
association between 
subjective cognitive 
decline and symptoms 
of depression, anxiety 
and psychosocial 
stress.  
Associations 
with 
subsequent 
dementia
Concept 
development
Method
development
Confounders
Current evidence 
support some 
association between 
SCD and future 
dementia. However, 
SCD is not specific 
enough to be a valid 
marker for cognitive 
decline on its own. In 
the presence of 
biomarker findings, 
the risk for further 
decline in SCD 
patients is high. 
A reduced awareness of cognitive 
difficulties may be present already 
at the MCI stage. Therefore, SCD 
should not be a required criterion 
for MCI. 
Memory clinic patients 
with SCD are younger 
and have higher 
education compared to 
MCI patients. 
A large proportion of memory clinic patients 
have subjective symptoms that cannot be 
objectively verified. Symptoms are important 
as triggers for help seeking. 
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